

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.

Wednesday, 9	Septen	nb <mark>er 20th</mark>				
09:30 - 10:00		Arrival, coffee				
10:00 - 10:15	15	Welcome and introduction	SN			
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON			
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON	4	T	X
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB	2	Y	Fe-
12:45 - 13:30	45	Lunch	200	Lind	7	¥.
13:30 - 14:15	45	Immunohistochemical principles The technical test approach - analytical phase If the s	MB			-
14:20 4/15:05	45	Immunohistochemical principles:	ISN	8.		
Region Syddanmark		The technical test approach - post-analytical phase I	SIN			1.2
15:05 - 15.25	20	Coffee				ANT.
15:2579eifus L	.IIIeDa	Immunohistochemical principles: The technical test approach post-analytical phase II	SN a			
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVI			
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)				

Thursday, September 21st

08:15 - 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45 45	Immunohistochemical classification of the unknown primary tumour – part I	MV
_09:50 - 10:10 _ 20	Coffee	
Henrik Hager	• Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
Dept. of Clinical Pathology	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 Yejle Hospital 30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Atriving feancer Age's standard	ized		
10:00 - 10:15	15	Welcomeand introduction 6	SN	1	
10:15 - 11:00	45	Immunohist ochemical princip les: The technical test approach – pre-analytical phase I	ON		
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON		
12:00 <mark>- 12:4</mark> 5	45	Immunohistochemical principles:	MB-	~	
12:45 - 13:30	45	Lunch		\sim	
13:30 <mark>- 14:1</mark> 5	45	Immunohistochemical principles:- The technical test approach - analytical phase II	MB	~~	\sim
14:20 <mark>- 19:0</mark> 5	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN		~
15:05 - 15.25	20	Coffee			
15:25 <mark>- 16:1</mark> 0	45	Immunohistochemical principles:	SN		
16:15 - 17:00		Immunohistochemical classification of breast			
1950	1960	1970mol 950 1990 2000 2010 1960 1970	1980 ^L	1990 2000	2010
17.00 - 19.00	AN	Social arrangement (optional) – Keglespil (Skittles)			
Thursday, Sept	tembe	r 21 st			
08:15 - 09:00	45 Females	Optimization of antibodies, selection, protocols - breast tumours	ASpriatio	on of the Nordic Canc	er Registries
09:00 - 09:45	45	Immunohistochemical classification of the	MV	8.7.2	016
	- Males	unknown primary tumour – part I			\sim
09:50 - 10 <mark>:1</mark> 0	20	Coffee			
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN		
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN		





Program

11:35 - 12:05

30

Wednesday, September 20th

Females ales 09:30 - 10:00 10:00 - 10:15_{Prostata} Welcome and introduction SN 15 Brvst 45 Immunohistochemical principles: Lunge (inkl. luftrør) 10:15 - 11:00ON The technical test approach – pre-analytical pha<mark>se</mark> 11:05 - 11:50 Immunohistochemical principles 45 ON Blære og andre urinveje The technical test approach – pre-analytical phase II 12:00 Endetaring g anus 45 Immunohistochemical principles MB Modermærkekræft, hud The technical test approach ^{herne og centranervesystem} Endetarm og anus Higher CentileBer Beystem 45 Lunch 13:30 - 1484als5vtkirtel 45 Immunohistochemical principles: Bugspytkirtel MB The technical test approach - analytical phasedel Ukendte og dårligt definerede 45 Immunohistochemical principlessiestok, æggeleder mv. 14:20 - 15:05 mfom SN The technical test approach - post-analytical phase I Nyre 15:05 - 15.25 Coffee 20 Non- Hodakin lymfom ıkæmi 15:25 - 16:10 45 Immunohistochemical principles: SN Leukæmi Mave The technical test approach - post-analytical phase II 16:15 - 17:00^{piserør} 45 Immunohistochemical classification of breast AVL Nvre tumours Lever 17.00 - 1900 harynx Social arrangement (optional) – Keglespil (Skittles) Lever Thursday, September 21st Skjoldbruskkirtel 08:15 - 09:00 Mundhule 45 Optimization of antibodies, selection, protocols and SN controls – breast tumours 09:00 - 09:45^{Strube} Spiserør Immunohistochemical classification of the 45 MV 5000 6000 1000 2000 3000 4000 1000 0 ²⁰Unkröwn primary⁰tumour – part I 09:50 - 10:10 20 Coffee Optimization of a ciber of the stige worgs of \$00.000 SN 10:10 - 10:4030 controls – unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the unknown printer of death / 100.000

Optimization of antibodies, selection, protocols and

SN

Region Syddanmark Sygehus Lillebælt

Immunohistochemcal classification of

Lung cancer,





		Im	munohistochemcal clas	sification of	f	Ω_{n}		
	^	L	ung cance	r,		Region Syddanmark Svigebus Lillebælt		
INOPOL	C	dia	anosis and predic	, tion				
Drogram			FITMINARY	lion.				
Fiogram						Alord	\mathbf{c}	
Wednesdayra	septen	ntrep 20 th	TABLE 1. 2015 WHO Classification of Lun	g Tumors ^{a,b,c}	TABLE 1. (Continued)			
		Arrival astro	Histologic Type and Subtypes	ICDO Code	Histologic Type and Subtypes	Program		
09:30 - 10:00		Arrival, corre	Adenocarcinoma	8140/3	Papillomas Squamous cell papilloma	Wednesday, 9	Septer	nber 20'
10:00 - 10:15	15	Welcome and		8250/3 ^d 8551/3 ^d	Exophyti SN	$^{8052/0}_{\sim}$ 30 - 10:00		Arrival, c
10:15 - 11:00	45	Immunohisto	chemical principles:	8260/3	Glandular papilloma	⁸² <u>4</u> 0.00 - 10:15	15	Welcome
		The technica	Micropapillary adenocarcinoma ^e	alvtica ^{8265/3}	Mixed squater Mnd glandular papilloma	⁸⁵⁶ 00:15 - 11:00	45	Immunoh
11.05 - 11.50	45	Immunohisto	Invasive mucinous adenocarcinomae	8253/3 ^d	Sclerosing pneumocytoma ^e	8832/0	45	The tech
11.05 - 11.50	чJ	The technice	CITCII NikaChivapyd mitchodspantiCS.	- lutio- ^{8754/36}	Alveolar adomina Tapillary adonoma	825140105 - 11:50 8260/0	45	Immunor The tech
	. –		rest and approver of the second	alytical plase	Mucinous cystadenoma	⁸⁴⁷ 20.00 - 12:45	45	Immunoł
12:00 - 12:45	45	Immunohisto	Chematical capitanciples:	8333/3 8144/3	Mucous gland adenoma Mesenchymal tuble	8480/0		The techr
		The technica	test ^{Miapproachamin} analytic	al phase I	Pulmonary hamartoma	8902045 - 13:30	45	Lunch
12:45 - 13:30	45	Lunch	Mucinous	8257/3 ^d	PEComatous tumors ^e	949930 - 14:15	45	Immunor The tech
13.30 - 14.15	45	Immunohisto	Preinvasive lesions	8250/0d	Lymphangioleiomyomatosis	$^{9174/1}_{24}$ 20 - 15:05	45	Immunoł
13.30 - 14.13	чJ	The technice		alabaaa TT	Clear cell tune	8/14/0		The tech
		The technica	i test approach - analytic	cai pnase 11	PEComa, malignant ^e	⁸⁷⁴ 5.05 - 15.25	20	Coffee
14:20014g13009pithel	ial t 45 10r	°s Immunohisto	chemical principles:	8070/3	Diffuse pulmorar Nymphangiomatosis	°15:25 – 16:10	45	Immunoh
(carcinom	ias)	The technica	test Keratinizio constanto solutione cell carcinome t-an	alyticallphas	eInframmatory myofibroblastic tumor	8825/1 oites: 15 - 17:00	45	Immunoł
15:05 - 15.25	20	Coffee	Basaloid squamous cell carcinoma ^e	8083/3	Pleuropulmonary blastoma	8973/3	45	tumours
15.25 - 16.10	45	Immunohisto	Preinvasive lesion	8070/2	Synovial sarcoma Pulmonary artery intimal sarcoma	${}^{9040/3}_{9137/3}00 - 19.00$		Social arr
15.25 - 10.10	73		Neuroendocrine tumors	- 1	Pulmonary mysel recommendation Pulmonary my	⁸ T ² hursday, Sep	tembe	r 21 st
		The technica	Lestalaの中市の自てい - post-an Combined small cell carcinoma		eM <u>to</u> epithelial tumors ^e Myoepithelioma	8 08 015 - 09:00	45	Optimiza
16:15 - 17:00	45	Immunohisto	chemical classification (of breast	Myoepithelial carcinoma	8982/3	_	controls -
		tumours	Combined large cell neuroendocrine carcinoma Carcinoid tumors	8013/3	Extranodal marginal zone lymphomas of mucosa-associated	_{9699/3} :00 - 09:45	45	Immunoh
17.00 - 19.00		Social arrand	ement"("öptional) – Keg	lespil ⁸² (Skitt	Lymphoid tissue (MALT lymphoma)	963003 EO 10,10	20	unknown
		- -	Preinvasive lesion		Lymphomatoid granulomatosis	97661^{1} 10 = 10.10	20	Ontimiza
Thursday, Sep [*]	tembe	r 21 st	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia	8040/0 ^d	Intravascular large B cell lymphoma ^e Pulmonary Langerhans cell histiocytosis	9712/3 10 10.10 9751/1	50	controls ·
08.15 00.00	45	Ontimization		8012/3	Erdheim-Chester disease	9750:45 - 11:30	45	Immunoł
08:15 - 09:00	45	Optimization	OI adehishistocchetsya SEIECLIOII Sarcomatoid carcinomas	, proceetors	Germ cell tunes	11 25 12 05		unknown
		controls – br		8022/3	Teratoma, mature	11:35 - 12:05	30	Optimiza
09:00 - 09:45	45	Immunohisto	chennical action of the second s	of the ^{8032/3}	Teratoma, increature Intrapulmonary infimoma	9080/1 85 $2310 - 13:00$	50	Lunch
		unknown prir	narv <mark>tumo</mark> ur – part I	8980/3	Melanoma	⁸² 13.00 - 13:45	45	Immunoł
09.50 - 10.10	20	Coffee	 Pulmonary blastoma Other and Unclassified carcinomas 	897/2/3	Meningioma, NOS Metastatic tumors	9530/0		tumours
10:10 10:10	20	Ontimination	Lymphoepithelioma-like carcinoma	8082/3	"The morphology codes are from the ICDO.2 Behavior is coded /0 for	$\frac{13:50}{\text{benign tumors}}$ - 14:20	30	Optimiza
10:10 - 10:40	30	Optimization	OT antipoentes, selection	, protocois	Profiles Specified, borderline or uncertain behavior, /2 for carcinoma in sin ntraepithelial neo(asi) and /3 for malignant tumors.	tu and grade III $-14.25 - 14.45$	20	Controis ·
		controls – un	known primary tumours	s parts43/3	 The classification is mounted from the previous WHO classification account changes in our understanding of these lesions. (This table is reproduced from the 2015 WHO classification by Trans- 	14:45 - 15:30	45	Immunoł
10:45 - 11:30	45	Immunohisto	chemilcal yclassification	of the 562/3	"These new codes were approved by the International Agency on Ca	ncer Research/		haemato
		unknown prir	nary ^{elemorphicademore} – part II	8940/0	"New terms changed or entities added since 2004 WHO Classificatio LCNEC, large cell neuroendocrine carcinoma, WHO, World Health	n. ³ 15:35 – 16:20 Organization;	45	Optimiza
11.35 - 12.05	30	Ontimization	of antibodies selection	(Continued)	CDO International Classification of Diseases for Oncology.	16:25 - 16:40	15	
11.JJ 12.UJ	50	opunization	-		SN SN	10.23 - 10.40	13	

		Imn	nunohistochemcal clas	sification of		\bigcirc		
				K		66		
Nord			ing cance	ſ,		Svaehus Lillebælt		
	/		encels and nucdic					
Program			ignosis and predic	tion.				
						Hordin		
Wadgesdayr Be	pten	drep 20 th	TABLE 1. 2015 WHO Classification of Lun	g Tumors ^{a,b,c} TAE	BLE 1. (Continued)			
		Arrival coffee	Histologic Type and Subtypes Enithelial tumors	ICDO Code Hist	apillomas	Program		
09.30 - 10.00		Allival, collec	Adenocarcinoma	8140/3	Squamous cell papilloma	Wednesday, S	epten	nber 20 ¹
10:00 - 10:15	15	welcome and	Acinar adenocarcinoma	8250/3 ^d 8551/3 ^d	Exophyti S N Inverted	8052/0 80990:30 - 10:00		Arrival, c
10:15 - 11:00	45	Immunohisto	chemicateprinciples:	8260/3 8265/3	Glandular papilloma	⁸² <u>0</u> 000 - 10:15	15	Welcome
		The technical	testapproach - pre-an	alyticaliphase	denomas	°10.15 – 11:00	45	Immunoł
11:05 - 11:50	45	Immunohisto		8253/3 ^d	Sclerosing pneumocytoma ^e Alveolar ademnina	8832/0 8211005 - 11:50	45	Immunoh
		The technical	test approach archiver and	alvticat ³⁴³ hase	Papillary adenoma	8260/0		The tech
12.00 - 12.45	45	Immunohisto	charefiledenterenoma pro an	8333/3	Mucinous cystadenoma Mucous gland adenoma	$^{84}720_{8480/0}$ 00 - 12:45	45	Immunoł
12.00 - 12.45	73	The technical		8144/3 Mes	enchymal tu	anh⊋av45 – 13·30	45	The tech
				cai pnase i ri	hondroma	922030 - 14:15	45	Immunoł
Adenocarcinoma	45	Lunch	Mucinous Preinvasive lesions	8257/3 ^d PI	EComatous tumors ^e	0174/1		The tech
13:30 - 14:15	45	Immunohisto	chemical principles:	8250/0 ^d	PEComa, benign	$^{91741}_{87440}$ 20 - 15:05	45	Immunoh
Squamous carcinoma		The technical	test apprioach - analytic	al phase II	Clear cell tuha PEComa, malignant ^e	8005/0 87145305 - 15 25	20	The tech
1 - 14 - 20 = 15 - 05 - 05	.45	Immunohisto	chemi ^{Mucinous} rinciples	8253/2 ^d C	ongenital peribronchial myofibroblastic tumor	$^{882741}_{882741}$ 25 - 16:10	45	Immunoł
Large cen neuroendoc	rine (Carcinoma ^{co}	toctkentinizingegramoesleril carcinomatt_or		iffuse pulmorar Nymphangiomatosis	8825/1	_	The tech
Small carcinoma	20		Nonkeradmizing squamous cell darcinoma ^e	8083/3	pithelioid hemangioendothelioma	9 115315 - 17:00	45	Immunoł
Sman String Can String	20	Conee	Preinvasive lesion	SUBJIS	ynovial sarcoma	9040/3 00 - 19 00		Social ar
15:25 - 16:10	45	Immunohisto		8070/2 Pt Pt	ulmonary artery intimal sarcoma ulmonary my Sch rcoma with EWSR1–CREB1 translocation ^e	^{9137/3} ⁸⁸ Thursday Sont	ombo	r 71 st
		The technical	testapproach - post-ar	alytical phase	I oppithelial tumors ^e		45	Ontimizai
16:15 - 17:00	45	Immunohisto	cheminal calassification	of breast	Myoepithelioma Myoepithelial carcinoma	8982/3	45	controls -
		tumours	Combined large cell neuroendocrine carcinoma	8013/3 Lym	nphohistiocy the Minlors	09:00 - 09:45	45	Immunoł
17 00 - 19 00		Social arrange		lesnil ⁸²	Lymphoid tissue (MALT lymphoma)			unknown
17:00 19:00			Preinvasive lesion		ymphomatoid granulomatosis	909250 - 10:10 97661 10 10:40	20	Ontimiza
Thursday, Septe	mbei	r 21 st	Diffuse idiopathic pulmonary neuroendocrine	8040/0 ^d In	ntravascular large B cell lymphoma ^e	9712/3 10 - 10.40	30	controls -
	4 5	Ontinsization	Large cell carcinoma	8012/3 Er	rdhejm-Chester disease	9 1 0:45 - 11:30	45	Immunoh
08:15 - 09:00	45	Optimization	OT addish@GaleSya SEIECTION Sarcomatoid carcinomas	, protocois af	erm cell tursel			unknown
		controls – bre	astitumours	8022/3	Teratoma, mature	11:35 - 12:05	30	Optimiza controls
09:00 - 09:45	45	Immunohisto	chemical classification (of the ^{8032/3}	Teratoma, investure htrapulmonary mymoma	9080/1 8582310 - 13:00	50	Lunch
		unknown prin	nary <mark>tumo</mark> ur – part I	8980/3 M	felanoma	⁸² 13.00 - 13:45	45	Immunoł
09.20 - 10.10	20	Coffee	• Pulmonary blastoma Other and Unclassified carcinomas	8972/3 M Met	astatic tumors	9530/0		tumours
10.10 - 10.40	30	Ontimization	Lymphoepithelioma-like carcinoma		The morphology codes are from the ICDO. ² Behavior is coded /0 for	13:50 - 14:20	30	Optimizat
10.10 - 10.40	20		Salivary gland-type tumors		epithelial neo ast and /3 for malignant tumors. The classification is modified from the previous WHO classification	$a_{n^3} t_{a} t_{i} t_{a} t_$	20	Coffee
		controis – uni	Adenoid cystic carcinoma	5 part 8430/3 accor	unt changes in our understanding of these lesions. This table is reproduced from the 2015 WHO Classification by Trav	is et al. 4:45 - 15:30	45	Immunoh
10:45 - 11:30	45	Immunohisto	cnemical classification (These new codes were approved by the International Agency on Ca	ncer Research/	4-	haemato
		unknown prin	hary"tumour"- part II	8940/0 (Continued)	New terms changed or entities added since 2004 WHO Classificatio LCNEC, large cell neuroendocrine carcinoma, WHO, World Health O International Classification of Discosce for Openloary	n. ³ 15:35 – 16:20 A Organization;	45	optimization controls
11:35 - 12:05	30	Optimization	of antibodies, selection	, protocols ar	nd SN	16:25 - 16:40	15	Discussio

		Immunohist	ochemcal classification of		Ω			
		Lung	cancer,		Region Syddanmark Sygehus Lill	ebælt		
INOIGU	/	diagnosis	and prediction	-				
Program		PRELIMIN	IARY					
Wednesdayra	oten	dates 20 th						
	T C	Arrival coffoo						
10.00 - 10.15	15	Welcome and introduc	tion	SN				
10.00 - 10.13 10.15 - 11.00	15 45	Immunohistochemical	nrincinles:	SN				
10.15 11.00	-10	The technical test app	roach — pre-analytical-phase Ir	ON I				
11:05 - 11:50	45	Immunohistochemical	principles: Patologity				2014	2
		The technical test app	Care analytical phase II			—	147	
12:00 - 12:45	45	Immunohistochemical	principles:					-
		The technical test app	Sourcener analytical phase fit karcin				0,8	
12:45 - 13:30	45	Lunch	Ikke småcellet karcinom				12,0	-
13:30 - 14:15	45	Immunohistochemical	Pranoiel falært karcinom	МВ			18,0	
Adenocarcinoma	4 5	The technical test app	roach - analytical phase II Adenokarcinom			—	39,9	-
Sauamous carcinom	45	Immunonistochemical	principles: Storaclestrateinom	SN			03	
15.05 - ut 5.25	20 ·		A dama alware gat langin are		0.2	_	0,5	
Large cell neuroend	ocrin 45	e Carcinoma			0,3	-	0,6	
Small cell carcinoma	1	The technical test ann	Neuroendokrin tumor	SN	0,7	_	0,9	
16:15 - 17:00	45	Immunohistochemical	Kassingation of breast	<i>u</i>	1,6		1,1	
		tumours	Anden malign primær lungecan	cer (NOS)	3.9	-	4.0	
17.00 - 19.00		Social arrangement (o	ptional) - Keplespil (<u>Skittles</u>)		17	-	2 5	
Thursday, Septe	mbe	r 21 st	Ingen patologi		5.4	-	2,9 5.2	
08:15 - 09:00	45	Optimization of antibo	diesa Felaction protocols and		1 706	-	/ 733	Λ
00110 00100		controls – breast tumo	ours	SN	4./00	-	4.755	4
09:00 - 09:45	45	Immunohistochemical	classification of the	MV				
		unknown primary tum	our – part I					
09:50 - 10:10	20	Coffee	Patologity	ре	2016	2015	2014	2
10:10 - 10:40	30	Optimization of antibo	Sinnst collection contocols and	k Lunge Cancer Gruppe & Dansk I	Lunge 2angeer	Reguter 14,9	15,4]
	_	controls – unknown pr	Share fremeurs padbkrint karcir	lom	0.9	0.8	0.8	
10:45 - 11:30	45	Immunohistochemical	classification of the	MV	92	104	123	-
	20	unknown primary tum),2 12.2	10,7	12,5	-
11:35 - 12:05	30	Optimization of antibo	onestoselleateon, karotooons and	SN	13,5	15,5	12,1	-



Lung cancer,



Wadpedayr	eipter	20 th	
09:30 -10:00	•••••	Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction SN	
10:15 - 11:00	45	Immunolistopper costiles: sampling ON The technical test approach – pre-analytical phase 18	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II ON	
12:00 - 12:45	45	Immunohistochemical principles: The tethnical test approach - analytical phase I	
12:45 - 13:30	45	Lanch Diagnosis	
13:30 - 14:15	45	Immunchistochemical principles: The technic metro matrice president of the tastas (T	'NM
14:20 - 15:05	45	Immunohistochemical principles: SN The technical test approach - post-analytical phase I SN	
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: Stage IA Stage IB The technical test approach post analytical phase II	
16:15 - 17:00	45	Immunohistochenging in Cal Chassification of breast No about T or N stage (including no tumours clinical staging information).	
17.00 - 19.00		Social arrangement (optional) - Keglespil (Skittles)	
Thursday, Se	ptembe	er 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and SN controls - Dreast tumours	
09:00 - 09:45	45	Immunohistochemical ² classification of the Tiabe Ni unknown primary tumour - partsi	
09:50 - 10:10	20		
10:10 - 10:40	30	Optimization of antibodies spection, protocols and solution of antibodies spection, protocols and solution of antibodies spectro of a solution	
10:45 - 11:30	45	Immunohistochemical classification of the MV unknown primary tumour – part II	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and SN	







Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee	
10:00 - 10:15	15 Welcome and introduction	BronchoscopeSN
10:15 - 11:00	45 Immunohistochemical principles:	ON ON
11:05 - 11:50	45 Immunohistochemical principles:	alvtical phase II ON
12:00 - 12:45	45 Immunohistochemical principles:	
12:45 - 13:30	45 Lunch	Bronklalwasn*
13:30 - 14:15	45 Immunohistochemical principles: The technical test approach - analytic	cal phase II MB Drugbbion cost
14:20 - 15:05	45 Immunohistochemical principles:	SN $DIUSIUUDDSY^*$
15:05 - 15.25	20 Coffee	FRUS*
15:25 - 16:10	45 Immu Biomisti ochemical principles: The technical test approach - post-ar	Nalytical phase II SN
16:15 - (17:00	§ 45 Immunohistochemical classification tumours	of breast AVL EUS*
17.00 - 19.00	Social arrangement (optional) Keg	pespil (<u>Skittles</u>)
Thursday, Sep	otember 21 st	2
08:15 - 09:00	45 Optimization of antibodies, selection	n, protocols and SN Biodsy S
00.00 00.45	K Controls – breast tumours	
09:00 - 09:45	unknown primary tumour – part I	or the MV
09:50 - 10:10	20 Coffee	
10:10 - 10:40	30 Optimization of antibodies, selection controls – unknown primary tumours	n, protocols and SN SN
10:45 - 11:30	45 Immunohistochemical classification	of the MV
11:35 - 12:05	30 Optimization of antibodies, selection	, protocols and SN





Program

Wednesday, September 20th

09:30 - 10:00Arrival, coffee 10:00 - 10:1515 Welcome and introduction SN 10:15 - 11:0045 Immunohistochemical principles: ON The technical test approach – pre-analytical phase I 11:05 - 11:5045 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II Immunohistochemical principles: 12:00 - 12:4545 MB The technical test approach - analytical phase I 12:45 - 13:30 45 Lunch 0 - 14:1545 Immunohist cal principles: MB The technica pproach - analytical phase II 0 - 15:0545 Immunohist cal principles: SN The technica pproach - post-analytical phase I 5 - 15.25 Coffee 20 16:10 45 Immunohist cal principles: SN pproach - post-analytical phase II The technica 5 - 17:00 45 cal classification of breast Immunohist AVL tumours 0 - 19.00(optional) Keglespil (Skittles) Social arrand rsday, September 21st 5 - 09:00 45 Optimization ibodies, selection, protocols and SN controls – br mours 0 - 09:45MV Immunohist cal classification of the 45 unknown pri umour – part I 0 - 10:10Coffee 20 0 - 10:40ibodies, selection, protocols and 30 Optimization SN primary tumours part I controls - ur 10:45 - 11:30Immunohistochemical classification of the 45 MV unknown primary tumour – part II 11:35 - 12:05 Optimization of antibodies, selection, protocols and 30 CN

Immunohistochemcal classification of

Lung cancer,







Program

Wednesday, September 20th

09:30 - 10:00Arrival, coffee 10:00 – 10: Mediastinescopy Icome and introduction SN 10:15 - 11:0045 Immunohistochemical principles: ON The technical test approach – pre-analytical phase I 45 Immunohistochemical principles: 11:05 - 11:50 Mediastinoscope ON The technical test approach – pre-analytical phase II 12:00 Incision:45 Immunohistochemical principles: 45 MB The technical dest approach - analytical phase I $Ridh 2 \mu 4 5 - 13:30$ Lunch 45 Immunohistochernical principles: 13:30 - 14:1545 MB The technical test approach - analytical phase II 14:20 - 15:05 Immunohistochemical principles: 45 **SN** The technical destination proach post-analytical phase I 15:05 - 15.25Coffee 20 15:25 - 16:10 Immunohistochemical principles: 45 SN The technical test approach - post-analytical phase II 16:15 - 17:0045 Immunohistochemical classification of breast AVL tumours National Cancer Institute 17.00 - 19.00Social arrangement (optional) – Keglespil (Skittle Thursday, September 21st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols an controls – breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the unknown primary tumour – part I 09:50 - 10:10 Coffee 20 10:10 - 10:4030 Optimization of antibodies, selection, protocols and SN controls – unknown primary tumours part I 45 Immunohistochemical classification of the 10:45 - 11:30 MV unknown primary tumour – part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



EBUS, EUS



SN







Patient selection in lung cancer: Evolution over time



Patient selection in lung cancer: Evolution over time





Morphology

Program

09:30 - 10:00

10:00 - 10:15

10:15 - 11:00

11.05 - 11.50

Wednesday, September 20th

15

45

Arrival, coffee

Welcome and introduction

Immunohistochemical principles:

Immunohistochemical principles:

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.

The technical test approach – pre-analytical phase I

The technical test approach – pre-analytical phase II





SN

ON

ON





Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.





cd56



all cell carcinoma

Wednesday,	Septen	iber 20 th		
09:30 - 10:00		Arrival, coffee		DAB
10:00 - 10:15	15	Welcome and introduction	SN	
Immunoh	istoc	The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON	
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB	
12:45 - 1 <u>2:3</u> 0	45	Lunch n63 cdl	56	
13:30 - 14:45	45	Immunohistechemical principles:		
14-20-405:05	2.45 M	The technical test approach - analytical phase II Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	C'area
15:05 - 15.25	20	Coffee		000
15.25 + 16:10	45	Immunohistochemical principles:	SNI O DA	
- 100 - MARCE A	ANO CIN	The technical test approach - post-analytical phase II	SHO OC	100
16:15 - 17:00	45-1	Immunohistochemical classification of breast	AVL	
17.00 - 19.00	Subel m	Social arrangement (optional) – Keglespil (Settles)	R A	and and
Thursday, Se	ptembe	r 21 st Large cell		C.ma
08:15 - 09:00	oma 45	Optimization of antibodies, selection new construction	ine carc	2111
<		controls – breast tumours	SN	•
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
09 $N O_{10,1}$ Sn	nall(Leing Carcinoma (NS	SCLC)	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	ŚŃ	
		controls – unknown primary tumours part I		
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV	

- 11:35 12:05 Optimization of antibodies, selection, protocols and 30 SN



Lung cancer,

diagnosis and prediction.



Diagnosis of Lung Cancer in Small Biopsies and Cytology Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; Ming Tsao, MD



Lung cancer, diagnosis and prediction.





Sygehus Lillebælt Step 1 **Positive Histology Positive Cytology** Keratinization, pearls and/or SQCC intercellular bridges

Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Ker, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thumissen, MD; MD; Ming Tsao, MD

Lung cancer,

diagnosis and prediction.





Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Ker, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunnissen, MD; MD; MIng Tsao, MD

Lung cancer, diagnosis and prediction.



CD56



Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W: Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunniseen, MD; Ming Tsao, MD



Lung cancer,

diagnosis and prediction.





Chromogranin A



Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Geisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunniseen, MD; Ming Tsao, MD



Lung cancer, diagnosis and prediction.



Synaptophysin



Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunniseen, MD; Ming Tsao, MD



Lung cancer, diagnosis and prediction.



Cytokeratin



Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Geisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Flieder, MD; Wilbur Franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W. Henderson, MD; Keith M. Ker, MD; Iver Petersen, MD; Victor Roggli, MD; Enk Thurnissen, MD; MD; Ming Tsao, MD



Lung cancer, diagnosis and prediction.



ttfl



Diagnosis of Lung Cancer in Small Biopsies and Cytology

Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification

William D. Travis, MD; Elisabeth Brambilla, MD; Masayuki Noguchi, MD; Andrew G. Nicholson, DM; Kim Ceisinger, MD; Yasushi Yatabe, MD; Yuichi Ishikawa, MD; Ignacio Wistuba, MD; Douglas B. Hieder, MD; Wilbur franklin, MD; Adi Cazdar, MD; Philip S. Hasleton, MD; Douglas W: Henderson, MD; Keith M. Kerr, MD; Iver Petersen, MD; Victor Roggli, MD; Erik Thunniseen, MD; Ming Tsao, MD



Lung cancer,





Lung cancer,









Lung cancer,








Lung cancer,







Lung cancer, diagnosis and prediction.









Adenocarcinoma



CK5/6

P63

Lung cancer, diagnosis and prediction.







ttfl

Napsin



Squamous carcinoma



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10 ⁴ roblems	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	
11:05 - 11:50	45	The technical test approach – pre-analytical phase II	P63+
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles The technical test approach 7 analytical phase II	MB
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee Coffee	
15:25 - 16:10	45	Immunohistoch <mark>emical principles:</mark> The technical te <mark>st approach - post-a</mark> nalytical phase II	SN
16:15 - 17:00	45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thursday, Septe	mbe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	Sc MV ^{Takah}
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN

p40 is the Best Marker for Diagnosing Pulmonary Squamous Cell Carcinoma: Comparison With p63, Cytokeratin 5/6, Desmocollin-3, and Sox2

Takahiro Tatsumori, MD.* † Koji Tsuta, MD, PhD.* Kyohei Masai, MD.* Tomoaki Kinno, MD.* Tomoko Taniyama, MD.* Akhiko Toshida, MD. PhD.* Koji Suzuki, MD. PhD.† and Hitosh Tsuda, MD, PhD*



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 -	10:00		Arrival, coffee		
10.0 ° €	blen	NS 15	Welcome and introduction		SN
10:15 -	11:00	45	Immunohistochemical principles:		
11:05 -	11:50	45 4	And Echnical test approach pre-analytical philipping a Carry The technical test approach – pre-analytical pha		°63+
12:00 -	12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I		МВ
12:45 -	13:30	45	Lunch No. Cases (%) Immunore	eactivity	
13:30 -	14:15	M at Fer	Immunohistochemical principles:	Positive	MB Mean Staining Score (0-300)
14:20 -	15:05	^{p40} _{p63} 45	The technical test approach - analytical phase I Immunohistochemical principiles:	1 153 (96.8) 150 (97.4) ase I	169 SN 237
15.05-SQ	£5.25	^{p40} 20	Coffee 418 405 (96.9)	13 (3.1)	1.3
15:25 -	16:10	^{p63} 45	Immunohistochemical principles: The technical test approach - post-analytical pha	14 (27.2) ase II	16.9 SN
16:15 -	17:00	45	Immunohistochemical classification of breast tumourskin breast prostate		AVL
17.00 -	19.00		Social arrangementr(toptional) - Keglespil (Ski	<u>ittles</u>)	
Thurso	day, Se	ptembe	r 21 st		
08:15 - 09:00 ectode	09:00 09:45 ^{mitmer}	45 ster 45	Optimization of antibodies, selection protocol controls - breast tumours Immunohistochemical classification of the unknown primary tumour - part I Cytoke	Best M Cell Ca eratin 5	Sanker for Diagnosing Pulmonary Arcinoma: Comparison With p63, /6, Desmocollin-3, and Sox2
09:50 -	10:10	2:0life	ativ Coffee Takahiro Tatsumori, M	1D,*† Koji 1	rsuta, MD, PhD,* Kyohei Masai, MD,* Tomoaki Kinno, MD,*
10:10 -	10:40	30 ^{pote}	^{tial} Optimization of antibodies, selection, optotocom controls – unknown primary tumours part I	፞ኇ ኯቒ [፟] ,* ₂ _{ar}	Akihiko Yoshida, MD, PhD,* Kenji Suzuki, MD, PhD,† SNitoshi Tsuda, MD, PhD*
10:45 -	11:30	45	Immunohistochemical classification of the unknown primary tumour – part II		MV
11:35 -	12:05	30	Optimization of antibodies, selection, protocol	s and	SN



Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



wedr	nesday, Sep	otem	ber 20							
09:30 -	. 10: Jable 2.	. Ser	vsitivijty	6fæpeci	ficity, P	PV and I	NPV of	markers u	ised in this	
10:00 - 10:15 -	10:51udy [%	45 45	Walkome Immunol	total st	diffied)	bles:		SN		
11:05 -	Marker	45 SI	The tech	ngal testi nistochem	approach icar princi	- Sigaratiti	pel phase :	^I PPV (%)	NPV (%)	
	ΔΝρ63(ρ	40)	\$l0€ tech	nical@est1	@ø<u>f</u>u@)ch	- p 1£0:0 a(812	2ø G∕⊉ }ase	1100 (16/16	i) 100 (32/32)	٦ ٦
12:00 -	- 12:45	45 ´	Immunol	ni <mark>stochem</mark> i nical@est1	ical princi approach	ples: - analyeidal@	h332)I	80 ^M B6/20)	100 (28/28)	
12:45 - 13:30 -	- 13:30 CK5/6 - 14:15	45 45	Sunch Immuno	81 (1) histochem	3/16) Ical princij	100 (32	2/32)	100 (13/13	3) 91 (32/35)	
	_ 34βE12		50€tech	nica⊕t⊈eşt <u>1</u>	≣p/p<u>1r6</u>a)ch	- ana47ti¢ <u>a</u> 159	₩ <u>3662</u>)II	47 (15/32)	94 (15/16)	
14:20 -	- 15:05 TTF1	45	Immunol	nica9e\$2	ical princi appfaach	ples: - post-7an(a)Q	(al3)hase	I 87 ⁵ 20/23)	80 (20/25)	_
15:05 - 15:25 -	- 15.25 - 16:10 - 16:10	20 45	<i>Coffee</i> Immunol	64 (10 histochem	6/25) ical princij	100 (23	8/23)	100 (16/16	i) 72 (23/32)	
	CK7		The tech	nicalores(2	Bp 203 ch	- posBanaBt	i @B phase	^{II} 63 (25/40)	100 (8/8)	
16:15 -	- 17:00 CK8/18	45	Immunol tabiours	nistochemi 100 (2	ical classif 25/25)	fication of b 35 (8/	reast 23)	63 ⁴ (25/40)	100 (8/8)	_
17.00 -	19.00 Sensitivity	v = TP	Social ar	rangemen ; Specific	t (optiona hty = TN/	/}_Keglesp /TN+FP;P(il (<mark>Skittle</mark> Sitive p	s) redictive valu	e (PPV) = TP/	
Thurs	day _r şepter	nber	' 21st 'e predic	tive valu	e (NPV) =	= TN/TN+F	N. FN in	dicates false	negatives: FP.	
08:15 -	- 09:00 false posi	45 tives;	Optimiza controls	tion of ant negative - breast ti	ibodies, s Sinours	election pr	stocols ai S.	nd SN		
09:00 -	- 09:45	45	Immunol unknown	nistochemi primary t	ical classif umour – j	fication of th part I	et J Clin Exp Pa www.ijcep.com,	thol 20147:4247-4253 /ISSN:1936-2625/IJCEP00	000624	
09:50 -	- 10:10	20	Coffee	1 /			Original	Article		
10:10 -	- 10:40	30	Optimiza controls	tion of ant – unknowr	tibodies, s n primary	election, protocological tumours pa	AND COLORING AND C	CK5/6NTTF-1 a	nd napsin A, a reliat	ole panel to
10:45 -	- 11:30	45	Immunol unknown	nistochemi primary t	ical classif umour – j	fication of th part II	Subtype	non-small cell MV	lung cancer in biops	y specimens

11:35 – 12:05 **30** Optimization of antibodies, selection, protocols and SN



Wednesday, September 20th

09:30 - 10: Table 2. Sensitivity repecificity, PPV and NPV of markers used in this 10:00 - 10:15 Udy [% positive total statien)] SN 10:15 - 11:00 ON PPV (%) 11:05 - 11:50 Subtypen selfstipper (%) - Specificity (%) -NPV (%) 500 technic <u>al</u> 000 techni ΔNp63(p40) 100(32/32)Immunohistochemical principles: 12:00 - 12:45 45 80^{MB6/20)} 100 (28/28) p63 She technical Qost 100103ch - an and aid a Bhaze) 12:45 - 13:30 13:30 - 14:15 Such 81 (13/16) 100 (32/32) Immunohistochemical principles: 45 100(13/13)91 (32/35) 45 47^{MB}(15/32) \$0€ technica9#e\$15ppf6ach - ana47ti¢a15ph3e2)II 94 (15/16) 34BE12 14:20 - 15:05 Immunohistochemićal principles: The technicablest approach - postar(algical3)hase I 87 (20/23) 45 TTF1 80 (20/25) 15:05 – 15.25 15:25 – 16:10 Coffee 20 AC 64 (16/25) 100 (23/23) Immunohistochemical principles: 100 (16/16) 72 (23/32) 45 The technical dest 20 p 20 ch - post and b 20 phase II 63 (25/40) 100 (8/8) CK7 Immunohistochemical classification of breast 16:15 - 17:0045 $63^{AV}_{(25/40)}$ 100 (8/8) CK8/18 100(25/25)tablours 35 (8/23) 17.00 – 19.00 Sensitivity = TP/TP+FN; Specificity = TN/TN+FP; Positive predictive value (PPV) = TP/ **Thursday, September 21st** Negative predictive value (NPV) = TN/TN+FN. FN indicates false negatives; FP, SN 09:00 - 09:4545 Immunohistochemical classification of the: J Clin Exp Pathol 201 MV 1:4247-4253 www.ijcep.com /ISSN:1936-2625/IJCEP0000624 unknown primary tumour - part I 09:50 - 10:10 Coffee 20 Optimization of antibodies, selection, protocols and 10:10 - 10:4030 controls - unknown primary tumours part p63, CK5/6, TTF-1 and napsin A, a reliable panel to Immunohistochemical classification of theubtype non-small cell lung cancer in biopsy specimens 10:45 - 11:30 45 MV unknown primary tumour - part II

11:35 – 12:05 **30** Optimization of antibodies, selection, protocols and SN

Immunohistochemcal classification of

Lung cancer,





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



09 Table:9. Alg	orith	Mriferce and introduction of poorly-differentiated non-small cell
1dung cercina	01 415 85	The technical test approach - pre-analytical phase I
	45	Immunohistochemical principles: <u>The technical test approach – pre-analytical phase II</u> ON
¹² ДП р63(р40)	CAR 5,	Испипоhistochemical principles: The technical test approach - analytical phase I MB Diagnosis
12 <mark>:</mark> 45 - 13:30 13:30 - 14:15	45 45	Lunch Immunohistochemical principles: Squamous cell carcinoma
+ 14:20 - 15:05	45 -	The technical test approach - analytical phase II Squamous cell carcinoma
15:05 - 15.25	20 -	Coffee + Adenocarcinoma
15:25 - 16:10 -	45 ₋	Immunohistochemical principles: The technical test approach - post-analytical phase II Adenocarcinoma
16:15 - 17:00	45 ₋	Immunohistochemical classification of breast tumours – – Poter Pot
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)
Thursday, Sept	embei	21 st non-Small cell carcinoma
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours SN
09:00 - 09:45	45	Immunohistochemical classification of the J Clin Exp Pathol 2014 (SSN:1936-2625/UCEP0000624)
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part Np63, CK5/6, NTTF-1 and napsin A, a reliable panel to
10:45 - 11:30	45	Immunohistochemical classification of the ubtype non-small cell lung cancer in biopsy specimens MV

11:35 – 12:05 **30** Optimization of antibodies, selection, protocols and SN



10⁴roblems¹⁵

Program

09:30 - 10:00

10:15 - 11:00

11:05 - 11:50

Wednesday, September 20th

45

45

Arrival, coffee

Welcome and introduction

Immunohistochemical principles:

Immunohistochemical principles:

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.

The technical test approach – pre-analytical phase I



SN ON ON

12:00 - 12:45	45	The technical test approach – pre-analytical phase II Immunohistochemical principles:	мв
12:45 - 13:30	45	The technical test approach - analytical phase I Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	мв
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN
¹ Different 17.00 - 19.00	ciaੀ o	Immunohistochemical classification of breast Detween primar Social arrangement (optional) – Keglespil (<u>Skittles</u>)	ryvand metastatic
Thursday, Sept	tembe	r 21 st carcinoma	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the	MV
09:50 - 10the		unknown primary tumour - part I adeno) carcinomas are po	ositive for ttfl
10:10 - 10:40	30`	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



WednesdaymSeptembero20tbchemistry results.

09:30 – 10: <u>00</u>	Arrival, coffee		
10:00 – 10:15 15	Welcome and introduction Total cases SPT24	SN 8G7G3/1	Р
10:15 - 11:00 45 Lung	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON	
11:05 – 11:50 Adenocar 4:5 on	a Immunohistochemical principles:85 134 (72.4%)	$ON^{121}(65.4\%)$	0.08
12:00 - 12:45 ^{Large Cell} 45	The technical test approach – pre-analytical phase II Immunohistochemical principles: 22(46.8%)	17(36.2%)	0.201
Carcinoid	The technical test approach - analytical phase4(60.8%)	4(17.4%)	0.003
12:45 – 13:30 45 13:30 – 14:15 <i>Squamous Cell</i>	Lunch Immunohistochemical principles: 97 14(16.8%)	1(1.0%)	0.003
Unclassified	The technical test approach - analytical phase (45.5%)	MB 7(31.8%)	0.26
14:20 – 15:05 45 Bladder	Immunohistochemical principles; The technical test approach - post-analytical phase I	SN 5 (5.1%)	NS
15:05 – 15.2 \$ Colon 20	Coffee 120 3 (2.5%)	3 (2.5%)	NS
15:25 – 16:10 45	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN 2(1.2%)	NS
16:15 – 17:0 §tomach 45	Immunohistochemical classification of breast (0.9%)	1(0.9%)	NS
Salivary Gland 17.00 – 19.00	tumours Social arrangement (optional) – Keglespil (<u>Skittles</u>)	AVL 1(1.8%)	NS
Squamous cell ca	arcinoma of head and neck 38 0(0%)	0(0%)	NS
08:15 - 09:00 Pancreatic aden	Carcinomas $0(0%)$ Optimization of antibodies, selection, protocols and	0(0%)	NS
Breast	controls – breast tumours 34 0(0%)	SN = 0(0%)	NS
09:00 – 09:45 45 NS: not significant	Immunohistochemical classification of the unknown primary tumour – part I	MV NIH Publ	ic Access script here Mol Marshal, Author manuscript: available in PMC 2011 March 1.
09:50 – 10:10 20	Coffee	Published in final edite Appl Immunohistoche	ed form as: en Mol Morphol. 2010 March ; 18(2): 142–149. doi:10.1097/PAI.0b013e3181bdf4e7
10:10 - 10:40 30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN Comparison o	of thyroid transcription factor-1 expression by two
10:45 – 11:30 45	Immunohistochemical classification of the unknown primary tumour – part II	MV tumors	maliaet Sinch Rafik Jacob Wesley O. Greaves Rosemarie Tavares Letic
11:35 – 12:05 30	Optimization of antibodies, selection, protocols and	SN School, Providence,	esnick, Ronald A. DeLellis, and Li J. Wang Jogy and Laboratory Medicine, Rhode Island Hospital and Brown Medical Rl.



Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



-

-

Wed	nesday, S	epterr	iber 20 th	Diagno	osis of I	meta	stasis
09:30 ·	- 10:00		Arrival, coffee	0			
10:00 ·	- 10:15	15	Welcome and introduc	ction 4	to the	Π	
10:15	- 11:00	45	Immunohistochemical	principles:			
			The technical test app	roach – pre-ar	nalytical phase I	ON	
11:05)	- 11:50	45	Immunohistochemic	(principles:		ON	Colon
0		TAR ANY	The technical test app	rpach – pre-ar	nalytical phase II	ON	CUIUII
12:00	- 12:45	45	Immunohistochemical	principles:		MB	
1.50	100	in the second	The technical test ap	fc ach - analyti	cal phase I	1.0	1 65 man
12:45	- 13:30	é 45	Lunch	loncin		1	
13 <mark>:30</mark>	- 14:15	45	Immunohistochemical	phineiples:	6.5	MB	10
1000	an Line of Sec.	1.0/	The technical test ap	K20 -analyti	ical phas	11	ALLAN
14:20	- 15:05	45	Immunohistochemical	principles.		SN	and II
and the	Contract of the second		The technical test app	revaen <post-a< th=""><th>malytical phase I</th><th>100</th><th></th></post-a<>	malytical phase I	100	
15:05	-15.25	20	Coffee	ER, , ,		- in all	
15:25	- 16:10	45	Immunohistochemical			SN	all and a second second
10 25	172 00		The technical test app	roaen - post-a	nalytical phase 11	S. 5	A State of the second
10:12	- 17:00	. 45	Immunonistochemica	Statsification	of brea	AVL	NOWN R 22
17.00	10.00		λ	(im		1 4	Contraction of the second
T / 100 -	- 19.00				Jiespii (Skittles		
Thurs	sday, Sept	embe	• 21 st	JK5/0	DR M		- 18-
08:15	- 09:00	45	Optimization of antibo	663 , selection	n, proto <mark>cols and</mark>		
68.99		Constant of the	controls - breast tum	°#590		511	
09:00	- 09:45	45	Immunohistochemical	classification	of the	MV	
S. WALS	and the second second		unknown primary tur	buil - part I			
09:50	- 10:10	20	Coffee	Ca125			
10:10	- 10:40	30	Optimization of antibo	odies, selection	n, protocols and	^d SN	
	11.00		controls – unknown 🏚	MANANS tumou	rs part I	0.1	
10:45	- 11:30	45	Immunohistochemica		of the	MV	

unknown primary tumour – part II Optimization of antiboder As a ection, protocols and 11:35 - 12:05 30 SN



Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Diagnosis of metastasis Wednesday, September 20th 09:30 - 10:00Arrival, coffee to the lung 10:00 - 10:1515 Welcome and introduction 10:15 - 11:00 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase I Immunohistochemic (principles: 11:05 - 11:50 45 Mamma ON The technical test approach - pre-analytical phase II 12:00 - 12:45 Immunohistochemical brinciples: 45 MD The technical test appropriate analytical phase I 12:45 - 13:30 45 Lunch Immunohistochemica Papeiples: 13:30 - 14:15 45 The technical test approphylical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN The technical test appleach - post-analytical pha 15:05 - 15.25 20 Coffee Immunohistochemical principles: The technical test approach - postanalytical phase 15:25 - 16:1045 SN 16:**1**5 - 17:00 45 Immunohistochemic Dasification of breast AVL tumours Social arrangement (Vittonal) – Keglespil (Skittles) 17.00 - 19.00CK5/6 Thursday, September 21st 08:15 - 09:00 Optimization of antiboties, selection, protocols and 45 SN controls breast tumoers 0 Immunohistochemical classification of the 09:00 - 09:4545 MV unknown primary turner part I 09:50 - 10:1020 Coffee Optimization of antibodies, selection, protocols and 10:10 - 10:40 30 SN controls – unknown PAX8 tumours part I

10:45 - 11:30 45 Immunohistochemical chasification of the MV unknown primary tumour – part II Optimization of antibook A A Bection, protocols and 11:35 - 12:05 30 SN





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Diagnosis of metastasis

09:30 -	- 10:00		Arrival, coffee	
10:00 -	- 10:15	15	Welcome and introduction to the li	IMO
10:15 -	- 11:00	45	Immunohistochemical principles:	
Sec. Sec.	1 - Carlos	The second	The technical test approach – pre-analytical phase I	ON
11:05 -	-11:50	45	Immunohistochemica (principles:	ON LIDDOR CI
		A Part and	The technical test approach – pre-analytical phase II	
12:00 -	- 12:45	45	Immunohistochemical principles:	MB
	AND A DESTRUCTION		The technical test appropriate analytical phase and the second se	
12:45 -	- 13:30	45	Lunch	Tanah - Anna and Carally
13:30 -	- 14:15	45	Immunohistochemica Shirieiples:	MB
1967 - 19 19	a barring the	1. 10/	The technical test appropriate analytical phase	
14:20 -	- 15:05	45	Immunohistochemical principles:	SN
1. Star	Children and the	100	The technical test approach - post-analytical particular	A DESCRIPTION OF
15:05 -	- 15.25	20	ER.	
15:25 -	- 16:10	45	Immunohistochemical principles	SN
a_			The technical test approach - post-analytical r	
16:15 -	- 17:00	45	Immunohistochemica Satsification of breas	AVE
17.00	10.00	all the	Control of the second of the second s	
17.00 -	- 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thurs	day, Septe	mbe	r 21 st CK5/6	
08:15 -	- 09:00	45	Optimization of antib of and protocols and	SN
	101010 - 200 - 20 - 20		controls - breast tumors of	511
09:00 -	- 09:45	45	Immunohistochemical classification of the	MV
-Wein-			unknown primary tuinguig part I	
09:50 -	- 10:10	20	Coffee Ca125	
10:10 -	- 10:40	30	Optimization of antibodies, selection, protocols and	SN
			controls – unknown hrift and tumours part I	
10.15	11.20	16	Immunohistochomical elacsification of the	

- 10:45 Immunohistochemica, classification of the unknown primary tumour – part II - 11:30 45 MV Optimization of antibook A A Bection, protocols and 11:35 - 12:05 30
 - SN





Lung cancer,



Program		PRELIMINARY		
Wednesday,	Septen	nber 20 th Diagnosis of n	netastas	sis
09:30 - 10:00		Arrival, coffee		
10:00 - 10:15	15	Welcome and introduction to the	LIMO	
10:15 - 11:00	45	Immunohistochemical principles:		
Sector Sector		The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	¥ . 45	Immunohistochemic (principles:	ON	
Constant Constant	Ban Barris	The technical test approach – pre-analytical phase II		
12:00 - 12:45	45	Immunohistochemica/principles: Ur	QENEIIAI	carcinoma
12.45 112.20	ALL COLOR	Ine technical test appreach - analytical phase I		
12:45 - 13:30	6 45	Lunch		
13:30 - 14:15	The states of	Immunonistocnemical principles:	MB	CARD AND AND AND AND AND AND AND AND AND AN
14,20 15,05	AF	Immunohistochomical principlas:		and the state
14.20 - 15.05	Chrones and	The technical test an Guach - nost-analytical phase	SN	De De Cartes de la compañía de
15.05 - 15.25	20			
15:25 - 16:10	45	Immunohistochemical principles:		A CLARKE
		The technical test approach - post analytical phase II	SN	
16:15 - 17:00	45	Immunohistochemic Cassification of breast	A MARKET AND A MARKET	10 mg
	a start	tumours	AVL	
17.00 - 19.00	18 18 A	Social arrangement (Uptional) – Keglespil (<u>Skittles</u>		
Thursday, Sep	otembe	r 21 st CK5/6		
08:15 - 09:00	45	Optimization of antibodies selection, protocols and		
The second s		controls - breast tumorts	SN	
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
		unknown primary turner for part I		
09:50 - 10:10	20	Coffee Ca125		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN	
		controls – unknown 🗗 🏔 🎖 tumours part I		
10:45 - 11:30	45	Immunohistochemical chassification of the	MV	
		unknown primary tumour – part II	- 	
11:35 - 12:05	30	Optimization of antibodes Action, protocols and	SN	



Lung cancer,



Program		FKELIMINAKY	
Wednesday,	Septem	nber 20th Diagnosis of n	netastasis
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction to the lu	IMO
10:15 - 11:00	45	Immunohistochemical principles:	
State of the state of the		The technical test approach – pre-analytical phase I	SN
11:05 - 11:50	45	Immunohistochemica (principles:	ONI II ·
12 00 12 45	A CARLES	The technical test approach – pre-analytical phase I	nal cell carcinoma
12:00 - 12:45	45	Immunonistocnemical principles:	МВ
12.45 - 13.30	45	lunch	
12.43 - 13.30	45	Immunohistochemica Napsines	
	See Children	The technical test aportagin- analytical phase	MB
14:20 - 15:05	45	Immunohistochemical principles:	
and the second second	Same and the second	The technical test appearer - post-analytical p	SN
15:05 - 15.25	20	Coffee FB	200
15:25 - 16:10	45	Immunohistochemical principles:	SN Charles Charles
9		The technical test approach - post analytical p	B
16:15 - 17:00	45	Immunohistochemic	AVL
17.00 10.00	Corner (State	Corini Astrongement Vim not Katlegnil (Chittles)	
17.00 - 19.00			
Thursday, Se	ptembe	r 21 st GK5/6	
08:15 - 09:00	45	Optimization of antiber 63, selection, protoco	
		controls - breast tumors	511
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tuinduit - part	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	controls unknown DiAVO turnoute part I	SN
10.45 - 11.30	45	Immunohistochemical dessification of the	
10.75 11.50	ΤJ	unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antiboil ATABection, protocols and	SN



Immunohistochemcal classification of

Lung cancer,



Program			
Wednesday, S	Septen	nber 20 th Diagnosis of m	netastasis
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction to the li	IMO
10:15 - 11:00	45	Immunohistochemical principles:	
Weller 2. Star		The technical test approach – pre-analytical phase I	ON
11:05 - 11:50	45	Immunohistochemidal principles:	Prostato
0	Sea Barris	The technical test approach – pre-analytical phase II	PriOstale
12:00 - 12:45	45	Immunohistochemical principles:	MB
ALL CONTRACTOR	ALL AND A	The technical test approach - analytical phase I	TID
12:45 - 13:30	6 45	Lunch	
13:30 - 14:15	45	Immunohistochemidal operations:	MB
and the second second		The technical test a prophy - analytical phase II	
14:20 - 15:05	45	Immunohistochemical principles:	SN
ALL CARACTER		The technical test approach - post-analytical phase I	and the second second
15:05 - 15.25	20		Nubble
15:25 - 16:10	45	Immunohistochemical principles:	SN
1 C a +7.00		Ine technical test approace + post-analytical phase II	Contraction of the second seco
10:15 - 17:00	45	tumours	AVL Rectum
17.00 10:00	ware for the second	Social arrangement Vimonal) Koglospil (Skittles)	Ditrasound
17.00 - 19.00			
Thursday, Sept	tembe	r 21 st CK5/6	
08:15 - 09:00	45	Optimization of antipocos, selection, protocols and	SN
		controls - breast tupours	
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tuniour – part I	
09:50 - 10:10	20	Coffee Ca125	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
10.45 11.20	4 5	controls – unknown proving tumours part I	
10:45 - 11:30	45	unknown primary turiour - part II	MV
11.35 - 12.05	30	Optimization of anti $\mathbf{A}\mathbf{A}\mathbf{A}\mathbf{A}$	
11.33 - 12.03	30		SN



Lung cancer,

diagnosis and prediction.



Program		INAKT	
Wednesday, Sep	tember 20 th	Diagnosis of n	netastasis
09:30 - 10:00	Arrival, coffee		
10:00 - 10:15	15 Welcome and introd	duction to the lu	IMA
10:15 - 11:00	45 Immunohistochemi	cal principles:	
and the second second	The technical test a	pproach – pre-analytical phase I	ON
11:05 - 11:50	45 Immun <mark>ohistochemi</mark>	c#(principles: C r	domotrial cancor
	The technical test a	pprpach – pre-analytical phase H	Idonneti lai Cancer
12:00 - 12:45	45 Immun <mark>ohistochemi</mark>	carprinciples:	MB
	The technical test a	p erfo ach - analytical phase	
12:45 - 13:30	45 Lunch	Nonoin	
13:30 - 14:15	15 Immunohistochemi	caNøhheibles:	
The second second	The technical test a	pppapp- analytical phase	
14:20 - 15:05	15 Immunohistochemi	cal principles:	SIN STREET
the constant of the	The technical test a	p pkoă<i>c</i>h - post-analytical p hase i	
15:05 - 15.25	20 Coffee	ER	
15:25 - 16:10	15 Immunohistochemi		SN
9	The technical test a	pproach - post-analytical prase II	u d for
16:15 - 17:00	45 Immunohistochemi	cap Sacification of breas	AVL
	tumours	λ/im	
17.00 - 19.00	Social arrangement	(optional) - Keglespil (Skittles)	
Thursday, Septen	nber 21 st	CK5/6	Ver PF
08.15 - 09.00	45 Optimization of ant	ib	
	controls - breast tu		The second second
09:00 - 09:45	45 Immunohistochemi	cal classification of the	Martin Contraction
	unknown primary t	undur grant I	
09:50 - 10:10	20 Coffee		
10:10 - 10:40	30 Optimization of ant	ibodies, selection, protocols and	
	controls – unknowr	PAX8 tumours part I	SN
10:45 - 11:30	45 Immunohistochemi	cal chassification of the	M) (
	unknown primary t	umour – part II	I''I V

SN

11:35 - 12:05 30 Optimization of antibook As A ection, protocols and



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Diagnosis of metastasis 09:30 - 10:00Arrival, coffee to the lung 10:00 - 10:1515 Welcome and introduction 10:15 - 11:00 45 Immunohistochemical principles: The technical test approach – pre-analytical phase I The technical test apprpach – pre-analytical phase II Ovarian cancer 11:05 - 11:50 45 12:00 - 12:45 Immunohistochemical brinciples: 45 The technical test approach - analytical phase 12:45 - 13:30 45 Lunch Immunohistochemica Parsiples: 13:30 - 14:15 45 The technical test approx - analytical phase 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical p 15:05 - 15.25 20 Coffee Immunohistochemical principles: The technical test approach - post analytical p 15:25 - 16:1045 ase II 16:**1**5 - 17:00 45 Immunohistochemic D Cassification of breas AVL tumours Social arrangement (Vittonal) – Keglespil (Skieces 17.00 - 19.00CK5/6 Thursday, September 21st 08:15 - 09:00 Optimization of antibotics, selection, protoc 45 controls breast tumoers 0 Immunohistochemical classification of the 09:00 - 09:4545 unknown primary turner part I

09:50 - 10:10Coffee 20 Optimization of antibodies, selection, protocols and 10:10 - 10:40 30 SN controls – unknown **PAX8** tumours part I Immunohistochemica, chasification of the unknown primary tumour – part II 10:45 - 11:30 45 MV Optimization of antibook A A B ection, protocols and 11:35 - 12:05 30 SN



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Diagnosis of metastasis

09:30 - 10:0	00	Arrival, coffee	
10:00 - 10:1	5 15	Welcome and introduction to the li	ING
10:15 - 11:0	0 45	Immunohistochemical principles:	
2012		The technical test approach – pre-analytical phase I	UN
11:05 - 11:5	50 · 45	Immunohistochemical principles:	ON
A CALL CONTRACT	Bear How	The technical test approach – pre-analytical phase II	ON
12:00 - 12:4	15 45	Immunohistochemical principles:	
100	a detailed a	The technical test appale in an alytical phase	
12:45 - 13:3	30 45	Lunch WT1	
13:30 - 14:1	.5 45	Immunohistochemical principles:	M
and the loss		The technical test approach - analytical phase	
14:20 - 15:0)5 45	Immunohistochemica principles:	
		The technical test approach - post-analytical prose	
15:05 - 15.2	.5 20	Coffee VIIII	
15:25 - 16:1	45	Immunohistochemi	
		The technical test approach - post-analytical phase	
16:15 - 17:0)0 45	Immunohistochemical classification of breas	· · · · · · · · · · · · / /
	and some liter	tumours	
17.00 - 19.0	0	Social arrangement (optional) – Keglespil (<mark>Skilles</mark>)	
Thursday	, September	r 21 st	and the second second
08:15 - 09:0)0 45	Optimization of antibodies, selection, protoco	and the second se
Section Section		controls - breast tumours	
09:00 - 09:4	15 45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:1	.0 20	Coffee	
10:10 - 10:4	10 30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	
10:45 - 11:3	30 45	Immunohistochemical classification of the	MV
		unknown primary tumour – part II	
11:35 - 12:0)5 30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
^{10:15} The		Improhistochemical principles:	conference
11:05 - 11:50	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
15:05 - 15.25	20	Coffee and the second s	ALL STRATEGY AND ALL STRATEGY A
15:25 - 16:10	-45	Innthunchistochemical principles: The technical test approach - post-analytical phase II	SN
16:15 - 17:00	19	Immunohistochemical classification of breast	AVL
17.00 - 19.00		ocial arrangement (optional) – Keglespil (Skittles)	
Thursday, Sep	5 100		my Z
08:15 - 09:00	1	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee de la constant	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	514
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN





Lung cancer,







Lung cancer,

diagnosis and prediction.



riogra			_	
Wedne	esday, Sept	emperization of opping a long	aiman	
09:30 - 1	0:00	raioanatomical spe	cimen	
10:00 - 1	0:15 1	5 Welcome and introduction	SN	
10:15 - 1	1:00 4	5 Immunohistochemical principles:	ON	
		The technical test approach – pre-analytical phase I		
11:05 – 1	1:50 4	5 Immunohistochemical principles:		
	Histology	The technical test approach – pre-analytical phase V		
$= \frac{12:00}{1} = 1$	2:45 4	5 Immunohistochemical principles:	мв	
		The technical test approach - analytical phase I		
12:45 - 1	Fixatio	5 LUNCN N Transverski stack seriest avia sintest		
13:30 - 1		5 . Immunonistocnemical principies:	MB	
14-20	Denya	Tatione technical test approach - analytical phase in	Smear preparation	1
17.20	🦰 Parafir	iembegoing al test approach - post-analytical phase I	SN	AKH KC01:5229 A. GIEMSA A. GIEMSA
	5.25 Micro	Sm Coffee		
15 25 -1	6:10	5 Immunohistochemical principles:		
		The technical test approach - post-analytical phase II	I SN	
16:15 - 1	7:00 4	5 Immunohistochemical classification of breast	A)/I	
A A		tumours	AVL	
17.00 – 1	9.00	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thursda	ay, Septem	ber 21 st		
08:15 - 0	9:00 4	5 Optimization of antipodies depetion, protocols and		
	- ·- ·			
09:00 - 0	9:45 4	5 Immunohistochemical classification of the	MV	
00.50 1	0.10 7	Coffee		
10.10 - 1	0.10 2	Optimization of antibodies selection protocols and	4	
10.10 - 1	J	controls – unknown primary tumours part I	' SN	
10:45 - 1	1:30 4	5 Immunohistochemical classification of the		
	•	unknown primary tumour – part II	MV	
11:35 - 1	.2:05 3	0 Optimization of antibodies, selection, protocols and		

SN



. . .

Immunohistochemcal classification of

Lung cancer,



Wednesday, Septer	mber 20 th	
09:30 - 10:00	Arrival, coffee	
10:00 – 10:15 15	Welcome and introduction	SN
10:15 – 11:00 45	Immunohistochemical principles:	ON
	The technical test approach – pre-analytical phase I	
11:05 - 11:50 45	Immunohistochemical principles:	ON
12·00 - 12·45 45	Immunohistochemical principles:	
12.00 12.45 45	The technical test approach - analytical phase I	MB
12:45 – 13:30 45	Lunch	
13:30 – 14:15 45	Immunohistochemical principles:	MB
	The technical test approach - analytical phase II	
14:20 – 15:05 45	Immunohistochemical principles:	SN
15.05 15.25 20	Ine technical test approach - post-analytical phase I	
15.05 - 15.25 20	Immunohistochemical principles:	A PARTY CO
13.23 10.10	The technical test approach - post-analytical phase II	SN
16:15 - 17:00 45	Immunohistochemical classification of breast	
	tumours	AVL
17.00 - 19.00	Social arrangement (optional) – Keglespil <u>(Skittles)</u>	
Thursday, Septembe	er 21 st	
- 08:15 - 09:00 45	Optimization of antibodies, selection, protocols and	
COD GENERAD SIDE	controls – breast tumours	SN AGE
09,00 - 09:45 45	Immunohistochemical classification of arge cell	MV Small call carcinoma
Adenocarcinoma	unknowle primary tandur part I neuroendocr	ine carc.
09:50 - 10:10 20		<i>V</i>
10:10 - 10:40 Non	optimization of antibodies, selection, protocols and	PNA .
10:45 - 11:30 45	Immunohistochemical classification of the	11a
	unknown prima tonour – part II	MV
11:35 – 12:05 30	Optimization of antipodies, selection, protocols and	SN



 ${}^{09:00}_{10:00} \bar{y}_{10:00}^{10:00} Ogy_{15}$

Program

10:15 - 11:00

11:05 - 11:50

12:00 - 12:45

12:45 - 13:30

13:30 - 14:15

14:20 - 15:05

15:25 - 16:10

17.00 - 19.00

08:15 - 09:00

09:00 - 09:45

09:50 - 10:10

10:10 - 10:40

10:45 - 11:30

11:35 - 12:05

5 - 17.00

Thursday, September 21st

Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,



_	Arrival, coffee		
15	Welcome and introduction C01-5229	SN	
45	Immunohistochemical principles: A. GIEMSA		
	The technical test approach - pre-analytical phase I	ON	
45	Immunohistochemical principles:		Marfalari
	The technical test approach – pre-analytical phase II	UN	Ινιοι τοιοάι
45	Immunohistochemical principles:	MR	5
	The technical test approach - analytical phase I	טויו	
45	Lunch		
45	Immunohistochemical principles:	MB	
	The technical test approach - analytical phase II		
45	Immunonistochemical principles:	SN	
20			
45	Immunohistochemical principles:		
75	The technical test approach - post-analytical phase II	SN	
45-0	Immunohistochemical classification of breast		
	tumours	AVL	TI :
	Social arrangement (optional) – Keglespil (<u>Skittles</u>)		Ininprep
mho	r 71 st		
45			mortologi
45	Optimization of antibodies, sele antrop protociols and	SN	
15	Immunohistochomical classification institute	M\/	
43	unknown primary tumour – partier of the c	1.1 A	
20			Cellblock
30	Optimization of antibodies, selections protocols and		
	controls – unknown primary tumotities up a return	SN	Immunocytologi←
45	Immunohistochemical classification of the	NA) /	. 3
	unknown primary tumour – part II	IMV	
30	Optimization of antibodies, selection, protocols and	CN	



Lung cancer,

diagnosis and prediction.



Wednesday, September 20th 1. Centrifuger materialet 10 min. ved 3000 omdr./min. ${}^{09}_{10} = \mathbf{\bar{y}_{10}^{10}} = \mathbf{\bar{y}_{10}^{10}} = \mathbf{O}_{10} = \mathbf{O}_{10}$ Arrival, coffee annelse 2. Hæld supernantanten fra. Welcome and introduction SN Immunohistochemical principles: 10:15 - 11:0045 The technical test approach – pre-analytical phase I Immunohistochemical principles. 11:05 - 11:5045 af The technical test approach - Tilset analytical freaternidehyd ON Immunohistochemical principles en gazepose, træk den over reagensglasset. 12:00 - 12:4545 koage The technical test approach - Innalytical phase I. 45 Lunch 9. Læg posen i en kapsel med mikroskopi-nummeret. 12.45 -13:30Immunohistochemical principles:et par dråber hæmatein på koaglet MB :15 45 hinPrep Present J91 The terminal test approach 1-1analyticalephasenell4% neutralt buffet formaldehyd. 14:20 - 15:05 45 Immunohistochemical principles: SN Immunity totogical test approach - post-analytical phase 15:05 15.25 20 Coffee 45 Immunohistochemical principles: Nonpoleonius — 16:10 Parafir SN The technical test approach - post-analytical phase II LIK . Link 10 Nanier Wa 16:15 - 17:0045 Immunohistochemical classification of breast AVL tumours 17.00 - 19.00rangement (optional) – Keglespil (Skittles) Thursday, Septe 08:15 - 09:00 Optimization of antibodies, selection, protocols and SN controls - breast tumours Indstøbning 9:00 - 09:45 Immunohistochemical classification of the MV 45 unknown primary tumour – part I 9:50 - 10:10Coffee 10:10 - 10:40Optimization of antibodies, selection, protocols and SN controls - un nown primary tumours part I 45 - 11:30 45 Immuno istochemical classification of the unknown primary tumour – part II

11:35 - 12:05

30

Optimization of antibodies, selection, protocols and



SN



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







12:45 - 13:30 DAB⁴⁵

Program

10:15 - 11:00

11:05 - 11:50

12:00 - 12:45

13:30 - 14:15

14:20 - 15:05

15:05 - 15.25

15:25 - 16:10

16:15 - 17:00

Wednesday, September 20th

45

45

45

45

45

20

45

Arrival, coffee

Lunch

Coffee

tumours

Welcome and introduction

Immunohistochemical principles:

Immunohistochemical principles:

Immunohistochemical principles:

Immunohistochemical principles:

Immunohistochemical principles:

The technical test approach vana Ntical phase I

Sekundært antistof

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.







MV

SN

		College cytoplasma
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)
Thursday, Sept	embe	21 st Cellekerne
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I
09:50 - 10:10	20	Coffee
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and



Patient selection in lung cancer: Evolution over time



Lung cancer, diagnosis and prediction.

Ideogram of chromosome 2 indicating the hybridization location

-250 kb -200 kb SPEC ALK Probe map (not to scale).

D2S

D252920

TheraScreen



Sygehus Lillebælt Step 1 **Positive Histology Positive Cytology**



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 -	10:00		Arrival, coffee	
10:00 -	10-15	15	Welcome and introduction	SN
10:15-	1600	45	Immunohistochemical principles:	
			The technical test approach – pre-analytical phase I	ON
1strima-057	11:50	45	Immunohistochemical principles:	ON
			The technical test approach – pre-analytical phase II	an Carl Ne lctor RTK
12:00	12.45	45 -	Immunohistochemical principles: 73 PP2	TK inhibitors
		Endothelial o	The technical test approach - analytical phase I	
1 m2une c4 55		45		\rightarrow GRB2 \rightarrow SOS \rightarrow RAS
13:30 -	1415 /)	45	Instruction of the second seco	MB / ↓
			The technical test approach - analytical phase II	RAF H RAF inhibitors
14:20 -	15:05	45	Immunonistochemical principles:	SN SN
1 - 0 -	1 - 2 -	20	The technical test approach - post-analytical phase 1 MB	
15:05 -	15.25	20	Coffee	Proteasome
15:25 -	16:10	45	Immunohistochemical principles:	SN SN
			The technical test approach - post-analytical phase II	
16:15 -	17:00	45	Immunohistochemical classification of breast	AVL
17.00	10.00			Transcription
17.00 -	19.00		Social arrangement (optional) - Keglespill (Skittles)	S
ThuPa	daw ay Sepite	anber	• 21 st	Cell-cycle progression Survival
08:15 -	09:00	45	Optimization of antibodies, selection, protocols and	Transcription factors
			controls – breast tumours	SIN 20000000000
09:00 -	09:45	45	Immunohistochemical classification of the	MV
			unknown primary tumour – part I	$\langle \cdot \rangle$
09:50 -	10:10	20	Coffee	\sim
10:10 -	10:40	30	Optimization of antibodies, selection, protocols and	SN
			controls – unknown primary tumours part I	SN
10:45 -	11:30	45	Immunohistochemical classification of the	MV
			unknown primary tumour – part II	
11:35 -	12:05	30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 -	10:00		Arrival, coffee	
10:00 -	10435	15	Welcome and introduction	SN
10:15-	1 FOR CV	45	Immunohistochemical principles:	
			The technical test approach – pre-analytical phase I	UN
1str ma - 05/	11:50	45	Immunohistochemical principles:	
			The technical test approach – pre-apalytical phase II	TK Stor
12:00	12.45	45 -	Immunohistochemical principles 7 PP2	Kinhibitors
		Endothelial c	The technical test approach analytical phase I	
1 m2uni r4 55-		4.5		\rightarrow GRB2 \rightarrow SOS \rightarrow RAS
13:30 -	14,15 /)	45	Inemunohistochemical principles:	MB /
			The technical test approach - analytical phase II	RAF - RAF inhibitors
14:20 -	15:05	45	Immunonistochemical principles:	SN SN
	1 - 2 -	~~	The technical test approach - post-analytical phase 1	
15:05 -	15.25	20	Coffee	Proteasome
15:25 -	16:10	45	Immunohistochemical principles:	SN SN
	17.00		The technical test approach - post-analytical phase II	
16:15 -	17:00	45	Immunonistochemical classification of breast	AVL
17.00	10.00			Transcription
17.00 -	19.00		Social arrangement (optional) - Keglespill Skittles)	
Thu 🕄	ac o det	₽₽₽	- 21 st	Cell-cycle progression Survival
08:15 -	09:00	45	Optimization of antibodies, selection, protocols and	Transcription factors Migration
_		\longrightarrow	controls – breast tumours	SN 2000000000
09:00 -	09:45	45	Immunohistochemical classification of the	MV
			unknown primary tumour – part I	$\langle \cdot \rangle$
09:50 -	10:10	20	Coffee	\sim
10:10 -	10:40	30	Optimization of antibodies, selection, protocols and	CN .
			controls – unknown primary tumours part I	
10:45 -	11:30	45	Immunohistochemical classification of the	MV
			unknown primary tumour – part II	
11:35 -	12:05	30	Optimization of antibodies, selection, protocols and	SN



Wednesday, September 20th

09:30 - 10:00Arrival, coffee welconcogene drivers' in Adenocarcinoma 10:00 - 10:1515 10:15 - 11:00 45 Immunohistochemical principles: ON Unknown The technical test approach - pre-analytical phase As (35%) 11:05 - 11:50 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II 12:00 - 12:45 45 Immunohistochemical principles: MB The technical test approach - analytical phase I 12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: MB The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN Gene Mutation The technical test approach - post-analytical phase I 15:05 - 15.25 20 Coffee 45051 Immunohistochemical principles: 15:25 - 16:10 SN Gene Fusion The technical test approach - post-analytical phase II 16:15 - 17:00KIE **45**RET Immunohistochemical classification of breast AV - Gene Amplification tumours Unknown 17.00 - 19.00Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st EGFR (15%) 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and SN controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the MV unknown primary tumour - part I 09:50 - 10:10 Coffee 20 10:10 - 10:4030 Optimization of antibodies, selection, protocols and SN controls – unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the MV unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and

SN

Region Syddanmark Sygehus Lillebælt

Immunohistochemcal classification of

Lung cancer,



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction vers in Adenocar	сврота
10:15 - 11:00	45	Immunohistochemical principles:	ON
11:05 - 11:50	Unknow 45	The technical test approach – pre-analytical phase is (Immunohistochemical principles:	35%) ON
12:00 - 12:45	45	Ine technical test approach – pre-analytical phase II Immunohistochemical principles:	MB
	mærk	Lunch Communohistochemical principles:	MB
14:20 - 15:55	45	The technical test approach - analytical phase II Immunohistochemical principles: The technical test approach - post-analytical phase I	SN Gene Mutation
15:05 - 15.25	20	Coffee	
15:25 - 16:10	4 Rost	Immunohistochemical principles: The technical test approach - post-analytical phase II	SN - Gene Fusion
16:15 - 17:00	KIF5B RET	Immunohistochemical classification of breast tumours	AV - Gene Amplification
17.00 - 19.00		Social arrangement (optional) – Keglespil (<u>Skittles</u>)	- F Unknown
Thursday, Se	eptember	EGFR (15%)	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee Duce	dictive marker
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN





Oncogene 'drivers' in Adenocarcinoma PRELTMINAR Program KRAS (35%) Unknown (32.5%) Wednesday, September 20th 09:30 - 10:00Arrival, coffee 10:00 - 10:15Welcome and introduction SN 15 10:15 - 11:0045 Immunohistochemical principles: ON The technical test approach - pre-analytical phase I Gene Mutation 11:05 - 11:5045 Immunohistochemical principles: O The technical test approach - pre-analytical phase II Gene Fusion 12:00 - 12:45 45 Immunohistochemical principles: MB Gene Amplification The technical test approach - analytical phase I - Unknown HER2 (2%) -12:45 - 13:30 45 Lunch EGFR (15%) 13:30 - 14:15 45 Immunohistochemical principles: ALK (5% MB The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles SN The technical test approach - post-analytical phase I 15:05 - 15.25Coffee 20 Immunohistochemical principles: 15:25 - 16:1045 SN The technical test approach - post-analytical phase II 16:15 - 17:00 DELETION OR 45 Immunohistochemical classification of breast AVL tumours GENE POINT MUTATION GENE AMPLIFICATION arrangement (OPTIONAL) GEMENDES (Skittles) Thursday, September 21st 08045 - 09:00Optimization of antibodies, Selection, propopols and SN kontrols - breast tumdurs $09.00^{A} - 09.45$ Immunohistochemical classification of the MV 45 Proteinown primary tumour - part I Hyperactive 09:50 - 10:10 10:10 - 10:40 ogerproduced regulatory transcribed gene Optimization of antibodies, selection, protocols and fusion to actively SN controls - unknowseprimary tumovespeartices 10:45 - 11:30 45 Immunohistochemicalindassificationiof phetein; MV unknown primar vernoul ced part II or fusion Optimization of antibodies, selection protein is 11:35 - 12:05 30

SN


0 Unknown (22 55

ROS1 (1%) KIF5B-RET (1.5%)-

Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



09:30 - 10:00		Arrival, coffee		
10-00-05	15	Welcome and introduction	SN	
	45	Immunohistochemical principles:	HER2,	TGFα Interleukin-8
•		The technical test approach – pre-analytical phase I		bF <mark>G</mark> F
Oncogene 'drivers' in Adenocarcinoma $11:05$ $11:50$	45	Immunohistochemical principles:		VEGF
		The technical test approach - pre-analytical phase II	UN	
12:00 - 12:45	45	Immunohistochemical principles:	MD	
Gene	Mutation	The technical test approach - analytical phase I	MD	
ROSI (1%) 2:45 - 13:30	Fusion 45	Lunch	SOS)	
HER2 (1.5%) 3:30 14:15	Amplification	Immunohistochemical principles:	MD	RAS 3
BRAF (4%)		The technical test approach - analytical phase II	- MD	Y >
14:20 ^{m=-} 15:05	45	Immunohistochemical principles;	SM	RAF
		The technical test approach - post-analytical phase Ip	JIN	
15:05 - 15.25	20	Coffee EGFR Tyrosine kinase MAPK -	MEK	
15:25 - 16:10	45	Immunohistochemical principles:	CN	
		The technical test approach - post-analytical phase II	JN	
16:15 - 17:00	45	Immunohistochemical classification of breast		
		tumours Cell proliferation 4	AVL	
17.00 - 19.00		Social arrangement (optional) – Keglespill (Scivities)	C	/
Thursday, Sep	tembe	r 21 st Tumor-induced neoangiogenesis	Transferring	-1
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	AP2	
		controls – breast tumours	SN	Tucicus
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part I		
09:50 - 10:10	20	Coffee		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	CN	Citarlana
		controls – unknown primary tumours part I	SIV	Cytopiasm
10:45 - 11:30	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part II	1.1 A	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN	

SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,



Wednesday, se	puci			
09:30 - 10:00		Arrival, coffee		
10 00 ±0 5	15	Welcome and introduction	SN	
	45	Immunohistochemical principles:	ON	
Oncogene 'drivers' in Adenocarcinoma		The technical test approach – pre-analytical phase I		
11:50 Unknown (325%)	45	Immunohistochemical principles:	ON	
12,00, 12,15	45	The technical test approach – pre-analytical phase II	-	
12:00 - 12:45	45	Immunonistocnemical principles:	MB	
Rost (15) - 45 - 13 - 3	45	Lunch EGER mutation positive		EGER mutation negative
KIF5B-RET (1.5%) - 13:30 - 14:15	45 ⁴¹⁰	Immunohistochemical principles:		Lei miniation negative
BRAF (4%)		The technical test approach is analytical phase II	MB	Gefitinih (n=91)
14:20 - 15:05	45	ក្ខាក់អឺរ៉ុមក្ខុohistochenជីចង់opkmin/plesitaxel (n=129) ត្ថ ^{1.0} ។		Carboplatin / paclitaxel (n=85)
		ŽThe technical test approach, cpost.andytica.ephaše I		HR (95% CI) - 2 85 (2 05 3 98)
15:05 - 15.25	20	°C0.#1e		p<0.0001
15:25 - 16:10	45	គ្នីmmunohistochemicalopavasia ទេនាវារាb, 97 (73.5%) ក្ខ័	SN 1	No. events gefitinib , 88 (96.7%)
	4 -	and technical test approaches of Paral (Hoal%) has an	1	No. events C / P, 70 (82.4%)
16:15 - 17:00	45	a mmunonistochemical classification of breast	AVL 🖣	<u>_</u>
17 00 - 19 00		Social arrangement (ontional) – Keglesnil (Skittles)	1	1
Thursday, Conto			<u>٦</u>	N
i nursday, Septe	mpe		<u>ب</u>	∼
08:15 - 09:00	45	20pti nization of antibodies selection protocols and	SN	
00.00 00.45	4 -	contiols – preast sumous 16 20 24	0 4	8 12 16 20 24
09:00 - 09:45	45	Immunonistocnemical sincation of the	IMIV	Months
09.50 - 10.10	20			
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and		
10110 10110		controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the	N/1\/	
		unknown primary tumour – part II	I*I V	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th





Lung cancer,



Frogram			
Wednesday, Se	pten	The Contents lists available at ScienceDirect	
09:30 - 10:00		Arrival, coffee Lung Cancer	hungcancer Attention
	15	Welcome and introduction mepage: www.elsevier.com/locate/lungcan	SN SN
1 0+153 1 1100	45	Immunohistochemical principles:	
		The technical test approach – pre-analytical phase I	ON
Oncogene 'drivers' in Adenocarcinoma	45	Improved EGER mutation-specific antibodies for lung adenocarcir	noma:
Unknown (32:5%)		The recific but not sensitive detection of an E746 A750 de	eletion in 🛛 🍟
12.00 - 12.45	15	exon 19 and an L858R mutation in exon 21 by immunohistocl	hemistry
12.00 12.45	73	The An Ma Seoght - The In Bark by A Van Jing C Ping Ji Sun ^a G Hyoiin Kim ^{a, C}	MB
Gene Mutation	• 	Hyun Chang ^a , Jin-Haeng Chung ^{a, C,*}	
ROS1 (1%) 2:45 - 13:30 Gene Fusion	45	Lunch Department of Pathology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi 463-707,	Republic of Korea
HER2 (1)3:30 - 14:15	45	Department of Pathology, Kyurpook National University College of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu 700-842, Repub Imp Childh Chills, Councel Michael (Pegel Charles and College of Medicine, 680 Gukchaebosang-ro, Jung-gu, Daegu	blic of Korea
BRAF (4%)		The adaptive provided the second seco	63-1701, III public of
14:20 - 15:05	45	Immunohistochemical principles:	Autophosphorylation
		The tempical fest approach - nest-analytical phase I 22	
15.05 - 15.25	20	Coffee	
15:05 15:25	20 45	Mutations associated	1.
15:25 - 16:10	45		SN
		Ine technical test approach - post-analytical phase if	
16:15 - 17:00	45	Immunohistochemical classification of breast and solution	
		tumours S768	
17.00 - 19.00		Social arrangement [®] ([®] ptional) [®] Kegles pil (Skittles) [®]	824
Thursday, Septe	mbe	r 21 st nucleotide-binding loop) Exon 19 Exon 20	Exon 21 (activation loop)
	4 E	Optimit SZPEn of pattern i AE746-AZIO ation protocol	L858R (40-45%)
08:15 - 09:00	45		ŚN ^{N8265} A839T
		Controis V689 preast tumours A/30 (ins A/1) (<1%)	K846R
09:00 - 09:45	45	Immunon stochemical classification of the	MV _{G863D}
		unknow f ⁷² primary tumour 1747-parts fr	(40–45%)
09:50 - 10:10	20	Coffee (5%) ΔL747-7751	
10:10 - 10:40	30	Optimization of antibodies 747 Selection, protocols and	
		CONTROLS associated ALT47-752 (E746V)	SN
10.45 - 11.30	45	Immunohistochemical classification of the	
10.42 - 11.20	-7.5		MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN

\bigcirc			Immunohi	istochemc	al classification	n of				
	_		Lunc	ı car	cer				Region Syddanmark	
Nordin			Lang	, cur					Sygehus Lillebælt	
			diagnos	is and p	rediction.					
Program			PRELIM		С н С н		 			
Wednesday, S	epten	nber 2 ()th	I T			37			
09:30 - 10:00	1.5.5	Arrival,	coffee					C CON		
	15	Welcom	e and introd	uction	Construction of the Construction of the	A MARINA	SN SN		E746-A750	
	45	Immun	phistochemic	al principl	es:		ON	S S S S S S S S S S S S S S S S S S S	del-specific AB	SPIII
Oncogene 'drivers' in Adenocarcinoma	45	Ine tec		pproacn –	pre-analytical ph	hase I	D P	Bar a Sta		
Unknown (325%)		The tec	nnical test a	oproach -	pre-analytical ph	nase II	ON S W			
12:00 - 12:45	45	Immund	histochemic	al principl	es:		MAR		E746 A750	
Gene Mu	tation	The tec	nnical test ap	oproach -	analytical phase !	I			del-specific AB	SPIII
ROS1 (1% 2:45 13:30 Gene Fut KIF5B-RET (1.5%) Gene Am	sion 45	Lunch					Charles and the second		dei-specific Ab	51111
HER2 (Em) 3: 30 + 14:15 EGFR (15%)	· 45	Immuno The tech	histochemic	al principl	es:		MB			
$\frac{14.20}{14.20} = 15.05$	45	Immun	histochemic	al principl	analytical phase			199 1210 1 (Million 179)		
Table 2	40	The tec	nical test a	oproach -	post-analytical pl	hase I	SN			
15:05 - 15.25 ^{Diagnostic}	powerof mu	itation-specific	antibodies compari	ng with EGFR mu	tational status.					
15:25 - 16:10 ^{Mutatior}	n-spe 4 i 5 ant	^{ib} Immuna	bhistocherrit	af principl	es: Sensitivity (%)	S	Specificity (%)	PPV (%)	NPV (%)	
Anti-EGF	R E746_A750	^{) d¶} he tec	nnica ^{[7} test ⁵ a Score 1 as	bositive	post-analytical pl	hase II	96.1%	80.0%	99.0%	
16:15 – 17:00	45	Immuno	ohistochemic	alitclassific	ation of breast		⁹⁹ AVL	92.3%	95.3%	
17.00 10.00		tumours	≥Score 3 as All deletions	positive	29.4%	1 .:	00.0% -	100.0%	89.6%	
17.00 - 19.00		Social a	rrangement		– Kęgiespii (<u>Si</u>	<u>kitties</u>)	96.6%	85.0%	86.0%	
Thursday, Sept	embe	r 21 st	\geq Score 2 as \geq Score 3 as \geq	positive	40.3% 16.1%	1	99.4% 00.0%	100.0%	77.4%	
08:15 - 09:00 Anti-EGF	R L858R 45	Optimiz	ation_gtranti	bodies, sel	lection, protoco	ols and	50 c0 %	30.7%	97.0%	
		controls	- breast 2tui	proves	80.4%		89.7%	64.9%	95.1%	
09:00 - 09:45	45	Immund	histochemic	al classific	cation of the	1	MV	100.0%	87.8%	
Abbreviatio	ons: PPV, posi	UNKNOW	in primary tu	imour – pá	årt I					
09:50 - 10:10	20	Coffee						201	Contents lists available at ScienceDirect Lung Cancer	lungcancer
10:10 - 10:40	30	Optimiz	ation of anti	bodies, sel	lection, protoco	ois and	SN	ELSEVIER journal	homepage: www.elsevier.com/locate/lungcan	
10.45 - 11.20	1 E			primary ti	uniours part I			Novel EGFR mutation-spec Highly specific but not sens exon 19 and an L858R mut	ific antibodies for lung adenocarcinoma: sitive detection of an E746_A750 deletion ir ation in exon 21 by immunohistochemistry	CrossMark
10.45 - 11.50	43	unknow	n primary tu	ai ciassiiic imoiir – na	ation of the		MV	An Na Seo ^{3,b,1} , Tae-In Park ^{b,1} , Yan Hyun Chang ^d , Jin-Haeng Chung ^{2, C,}	Jin ^{2,,,} Ping-Li Sun ^{2,,,} Hyojin Kim ^{2,,,}	
11:35 - 12:05	30	Optimiz	ation of antil	bodies, sel	lection, protoco	ols and	CN	^b Department of Pathology, Kyangpook National Ultiversity ^c Department of Pathology, Seeul National Ultiversity College ^d Department of Internal Medicine, Social National University Karea	Cadege of Healizine, 620 Calcibodosumpa, Jung pa, Dongo '100-452, Papulate of Karna 1994 (Malissian, 102 Sanahar), Jungsang, page 2011 10-728, Rapida of Karna 9 Bandang Heapitel, 300 Cami-deng, Bandang gu, Seongasan-si, Gyeonggi 463-707, Rapublic o	r -
		•		, -	, ,					





11:35 - 12:05

30

Wednesday, September 20th

09:30 - 10:00Arrival, coffee Welcome and introduction SN 15 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase I Oncogene 'drivers' in Adenocarcinoma 11:5045 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II 2:00 12:45 45 Immunohistochemical principles: The technical test approach - analytical phase I 45 Lunch ROS1 (1%) - 2.45 13:3Gene Fusion **45** Immunohistochemical principles: - Unknown The technical test approach - analytical phase 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase I 15:05 - 15.2520 Coffee 15:25 - 16:10 45 Immunohistochemical principles: SN The technical test approach - post-analytical phase II 16:15 - 17:0045 Immunohistochemical classification of breast AVL tumours 17.00 - 19.00Social arrangement (optional) – Keglespil (Skittles) Thursday, September 21st Analysis (template) election, protocols an 08:15 - 09:00 45 SN controls – breast tumours 09:00 - 09:45 45 Immunohistochemical classification of the MV unknown primary tumour - part I Coff 09:50 - 10:1020 Optimization of antibodies, selection, protocols and 10:10 - 10:4030 SM controls – unknown primary tumours part I 1 Tissuel seation 45 Immunohistochemical classification of the MV unknown primary tumour - part II

Optimization of antibodies, selection, protocols and

SN

Immunohistochemcal classification of

Lung cancer,





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







2:00

450

Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.





Oncogene 'drivers' in Adenocarcinoma

SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
	45	Immunohistochemical principles:	
Oneogono (drivore) in Adoneografinomo		The technical test approach – pre-analytical phase I	ON
	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase II	ÖN
12:00 - 12:45	45	Immunohistochemical principles:	MB
- Gene Mutation		The technical test approach - analytical phase I	
ROS1 (1%) Gene Fusion	45	Lunch	
HER2 (25%) 3 3 4 4 1 5 EGFR (15%)	45	Immunohistochemical principles:	
BRAF (4%) ALK (5%)		The technical test approach - analytical phase II	
14:20 - 15:05	45	Immunohistochemical principles:	SN S6K
IF OF IF OF EML4		The technical test approach - post-analytical phase I	mTOR
15:05 - 15:28	20	AKT	-
15:25 - 16:10	45	Immunonistochemical principies:	SN
16.15 17.00	45	The rechnical less approach - post-analytical phase II Pisk	
10.13 - 17.00	45	tumours	AVL Proliferation
17 00 - 19 00		Social arrangement (ontional) - Keglesni (Skittles)	
17.00 19.00			\rightarrow RAS \rightarrow MEK \rightarrow ErK
Thursday, Septe	mbe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	
		controls – breast tumours	sion I
09:00 - 09:45	45	Immunohistochemical classification of the prote	irim V
		unknown primary tumdur – part I	PIP ₂
09:50 - 10:10	20	Coffee	÷
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN IP3
		controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunonistochemical classification of the	WV American Association for Cancer Research
11.25 12.05	20	Unknown primary tumour - part II	2/100
11:32 - 12:03	20	opumization of antibodies, selection, protocols and	SN



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,



09:30 - 10:00		Arrival, coffee			
10:00 + 10:15	15	Welcome and introduction	SN		
	45	Immunohistochemical principles: The technical test approach – pre-analytical phase I	ON		
Unknown (325%)	45	Immunohistochemical principles: The technical test approach – pre-analytical phase II	ON		
12:00 - 12:45	45	Immunohistochemical principles: The technical test approach - analytical phase I	MB		
ROSI (1%)-2:45-13:30 Gene Fu	^{usion} 45 ^E				
130 - 14:15 Gene An	^{mplification} 45	Immunohistochemical principles:	MB	ALK	
BRAF (4%)		The ⁶ technical test approach - analytical phase II	МВ	ALK	
14:20 - 15:05	45	Imenukazohistochemical principerate	SN	ALK	
15.05 - 15.25	20	The technical test approach - post-analytical phase I	511	ALK	
15.05 - 16.10	4 5	Immunohistochemical principlesML4		ALK	
13.23 10.10	-10	The technical test approach - pose statical phase II	SN	ΔΙΚ	
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	ALK	
17.00 - 19.00		Social arrangement (optional) - EKeglespil (Skittles)		ALK	
Thursday, Sept	tembe	TFG TFG		ALK	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	CN	ALK	
		controls – breast tumours	SN	Tvrosine	kinase domain
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV		
09:50 - 10:10	20	Coffee			
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN		
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN		



09:30 - 10:00

10:00 - 10/15

ROS1 (1%)

BRAF (4%

Oncogene 'drivers' in Adenocarcinoma 11:50

ALK (5%)

14:20 - 15:05

15:05 - 15.25

15:25 - 16:10

16:15 - 1志:00

17.00 - 19.00 0

08:15 - 09:00

09:00 - 09:450-

09:50 - 10:10

10:10 - 10:40

11:35 - 12:05

20-

-60

-100 -

Figure 2: Waterfall plot showing

Massachusetts Medical Society.)

2:45

Wednesday, September 20th

15

45

45

45

45

45

45

20

45

45

45

45

20⁰

30

30

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.

Optimization of antibodies, selection, protocols and



Rx only

AP



SN



Wednesday, September 20th

09:30 - 10:00Arrival, coffee Welcome and introduction 10:00 - 10/15 15 45 Immunohistochemical principles: The technical test approach – pre-analytical phase I Oncogene 'drivers' in Adenocarcinoma 45 Immunohistochemical principles: The technical test approach – pre-analytical phase II .2:45 45 Immunohistochemical principles: The technical test approach - analytical phase I 45 Lunch **45** Immunohistochemical principles: The technical Desteoptiach of an fusion of the stop of BRAF (4% 14:20 - 15:05 45 Immunohistochemical principles: The technical test approach - post-analytical phase I 15:05 - 15.25Coffee 20 Immunohistochemical principles: 15:25 - 16:10 45 Detection of chromosomot technical test approached to be an alytical phase I 16:15 - 17:00 45 Immunohistochemical classification of broast changes tumours Social arrangement (optional)_{rg} Keglespil 17.00 - 19.00KIF5B-ALK Thursday, September 21st Coiled-coil domain 08:15 - 09:00 45, ALK Optimization of antibodies, selection, protocols and ALK-Fusion controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the unknown primary tumour - part I 09:50 - 10:10 20 Coffee 10:10 - 10:4030 Optimization of antibodies, selection, protocols and controls - unknown primary tumours part I 45 10:45 - 11:30 Immunohistochemical classification of the unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.

Svgehus Lillebælt

Detection of fusion protein

SN

ON

ON

MB

MB

SN

SN

SN

MV

SN

MV

SN





BRAF (4%

Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,









SPEC ALK Dual Colar Break Apart Probe ybridized to normal interphase cells as indicated orange/green huion signals per nuch





Wednesday, September 20th

Arrival, coffee **RT-PCR** Welcome and introduction 09:30 - 10:00SN 10:00 - 10/15 15 45 Immunohistochemical principles: ON The technical test approach - pre-analytical phase Oncogene 'drivers' in Adenocarcinoma Immunohistochemical principles 45 The technical test approace the action of the primers 2:45 45 Immunohistochemical principles: MB The technical test approach **J**analytical phase 45 Lunch ROS1 (1%) Immunohistochemical principles: **45** HER2 1 ALK MB The technical test approach - anal Midal phase II ALK (5%) BRAF (4% 14:20 - 15:05 45 Immunohistochemical principles: ALK SP EML4 The technical test approach - post-analytical phase I Unknown EML4 ALK 15:05 - 15.25Coffee 20 E17; A20 E13;A20 EML4 ALK E2; A20 15:25 - 16:10 45 Immunohistochemical principl Variant 1 SNE15; A20 33% The technical test approach - postanalytica phase II AIK E18; A20 16:15 - 17:0045 Immunohistochemical classification of breast E14; A20 ALK AVL tumours Variant 3a/b E20; A20 E13; A20 17.00 - 19.00Social arrangenfent (optional) – Keglesbi Skittles ALK E6a/b; A20 Thursday, September 21st Detection of fusion RNA E17:A20 EML4 ALK sion Optimization To all ibodies, selection, protocols and ALK SNEML4-ALK cantrols - breast-tumours KIE5B ALK E13:A20 Immunohistochemical classification of the E6:#99:00 - 09:45 EML4 45 MV E20:A20 Tyrosine kinase domain uĥknown primary tumour – part f^{oiled-coil domain} E14;A20 EML4 Coffee E1809:50 10:10ML4 20 10:40 EML4 EML4 $E^{15;A^2}_{E^2;A^{20}}$:10 -Optimization of antibodies, selection, protocols and SN controls - unknown primary tumours part I E17;A20 45 Immunohistochemical classification of the TFG-ALK10:45 - 11:30MV KIF5B-ALK uĥĥnown primary tumour – part II Coiled-coil domain 11:35 - 12:0530 Optimization of antibodies, selection, protocols and SN

Immunohistochemcal classification of

Lung cancer,





Wednesday, September 20th

Arrival, coffee **RT-PCR** Welcome and introduction 09:30 - 10:00SN 10:00 - 10/15 15 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase i Oncogene 'drivers' in Adenocarcinoma Immunohistochemical principles 45 The technical test approache technical test approache technical test approache te 2:45 45 Immunohistochemical principles: MB The technical test approach - analytical phase 45 Lunch ROS1 (1%) Immunohistochemical principles: **45** HER2 ALK MB The technical test approach - analytical phase II ALK (5%) BRAF (4% 14:20 - 15:05 45 Immunohistochemical principles: EMU ALK C The technical test approach - post-analytical phase I Unknown EML4 ALK 15:05 - 15.25Coffee 20 E17; A20 E13;A20 15:25 - 16:10 45 Immunohistochennical principles EML4 ALK E2; A20 Variant 1 SN E15; A20 The technical test approach - postanalytica 33% phase II_{AIK} E18; A20 16:15 - 17:0045 Immunohistochemical classification of breast E14; A20 ALK AVL tumours E20; A20 E13; A20 17.00 - 19.00Social arrangement (optional) - Kedlespild Skittles) E6a/b; A20 Thursday, September 21st Detection of fusion RNA EML4 E17:A20 ALK Optimization Top-AHtibodies, selection, protocols and ALK SNEML4-ALK controls - breast tymours KIE5B ALK FMI 4 E13:A20 Immunohistochemical classification of the E6:#99:00 - 09:45 EML4 45 ΜV E20;A20 Tyrosine kinase domain uĥknown primary tumour - part foiled-coil domain E14;A20 EML4 Coffee E1809:50 10:10ML4 20 10:40 EML4 122320 1220Optimization of antibodies, selection, protocols and SN controls - unknown primary tumours part I E17;A20 45 Immunohistochemical classification of the TFG-ALK10:45 - 11:30MV KIF5B-ALK uĥĥnown primary tumour – part II Coiled-coil domain 11:35 - 12:0530 Optimization of antibodies, selection, protocols and SN

Immunohistochemcal classification of

Lung cancer,





Lung cancer,









Wednesday, September 20th

09:30 - 10:00 10: 00 - 10: 15 15	Arrivel come and unohistochemistry	SN
10 /13 L1 00 45	Immunohistochemical principles:	ON
Oncogene 'drivers' in Adenocarcinoma	Immunohistochemical principles:	ON
12:00 - 12:45 45	Immunohistochemical principles:	мв
ROSI (191-2:45-113:30 Gene Fusion 45	Lunch	
HER2 (1,3): BRAF (4%)	Immunohistochemical principles: The technical test approach - analytical phase II	MB
14:20 ^{mer (45)}	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN
$De_{15:25}^{15:05}\bar{on}_{16:10}^{15:25}$ fusion ₄ gro	Coffee Immunohistochemical principles:	SN
16:15 - 17:00 45	Immunohistochemical classification of breast tumours	AVL
17.00 - 19.00	Social arrangement (optional) - Keglespil (Skittles)	ALL STORAGE AND
Thursday, September	- 21 st	
08:15 – 09:00 45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09 <mark>:45 45</mark>	Immunohistochemical classification of the unknown primary tumour – part I	[™] Ventana
09:50 - 10:10 20	Coffee	
10:10 APK fusion 0	Optimization of antibodies, selection, protocols and controls – unknown perfect surful is padepender	f®Nof fusion partner
10:45 - 11 protein 45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 – 12:05 30	Optimization of antibodies, selection, protocols and	SN

Immunohistochemcal classification of

Lung cancer,





Wednesday, September 20th

09:30 - 10:00Arri Manunohistochemistry SN 15 10:00 10.15 45 Immunohistochemical principles The technic Concentrated antibodies n Vendor Suff.1 Suff. Optimal Good Borderline Poor Oncogene 'drivers' in Adenocarcinoma OPS² Immunohistochemicar princ 431 Elica/Novocastra 45 ÓN The technical test approach + pre-analytical phase II Immunohistochemical principlesnosan 15 24 7 34% 22% 45 2:45MB The technical test approach ¹/₂ analytical phase mAb clone ALK1 0 0 0 3 45 Lunch 1 Cell Marque **~**45 Immunohistochemiesionnaidi Signaling 6 12 3 2 78% 94% 3 MB 0 **1**0 The technic Ready-To-Use 0 100% 100% BRAF (4% 14:20 - 15:05 45 Immunohist antibodies The technican approach & postronalytical phase 1 0 6 0 Detection of fusion aprotein mab clone 5A4 1 Maixing the second s 1 Maixin 0 0 1 SN 1 0 The technical Alege approach 1 post-analytical phase II 0 16:15 - 17:00 **45** Immunohist<u>ជ្ជុះក្នុងក្រុងក្រ</u>ុង classificatioគៈល£ breast AVL⁰ 0 1 tumours mAb ALK1 Social arran definent (optional) – Keglespil (Skittles) 0 8 1 17.00 - 19.000 0 4 GA641 Thursday, September 21st mAb clone ALK1 2 5 7 Ventana 0 0 Optimization 790 f 800 2918 of antibodies, selection, protocols and controls – brackst tumours 1 BioGenex 0 08:15 - 09:00 45 SN Λ 0 1 09:00 - 09:4545 12 MV 4 Immunohistochemiesisication of the 53 1 93% 100% unknown primary by by by part I 2 Ventana 1 0 0 1 -09:50 - 10:10 790-4796³ 20 Coffee Optimizationa antibodies, selection protocols and o 10:10 APK fusion 0 0 SN controls – u_{Total} y_stumours part I 72 43 43 31 -10:45 - 11**protein 45** Immunohist Proportion sification of the 38% 23%MV 23% 16% 61% unknown printerwortei sufficient stains (a tinter b] good). 2) Proportion of sufficient stains with optimal proto imal protocol settings only, see below. . 3) RTU system developed for the Ventana BenchMark 11:35 - 12:05Optimization of antibodies, selection diffrotocols approver and Autostainer) 30

Immunohistochemcal classification of

Lung cancer,





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







Lung cancer,

diagnosis and prediction.



Wednesday, September 20th 09:30 - 10:00Arrival, coffee Algorithmsn Welcome and introduction 10:00 - 10.15 15 45 Immunohistochemical principles: ON The technical test approach - pre-analytical phase I Oncogene 'drivers' in Adenocarcinoma 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II IHC MB 2:0012:45 45 Immunohistochemical principles: The technical test approach - analytical phase 45 Lunch **45** Immunohistochemical principles: MВ The technical test approach analytical phase I BRAF (4% 14:20 - 15:05 Immunohistochemical principles Equivocal 45 Positive The technical test approach - post-analytical phase I 1+/2+ 3+ Detection of fusion aprotein Coffee SN The technical test approach - post-analytical phase II 16:15 - 17:0045 Immunohistochemical classification of breast AVL tumours FISH Social arrangement (optional) -Reported as Keglespil (Skittles) 17.00 - 19.00ALK-negative ALK-positive Thursday, September 21st 08:15 - 09:0045 Optimization of antibodies, selection, protocols and SN controls - breast tumours Improving Objection : differing for AL# 5 hibiton interaching to chemical classification of the MV Non–Small Cell Lung Cancerunknown primary tumour – paralidated negative Validated positive A Pooleste Date Analysis on Diagnostic Opporting Charge stics of 10 – 10:40 Detimization of antibodies, selection, protocols and 10:10 - 10:40 SN Jianrong Zhang, MD, † Jingpei Li, MD, † Yang Liu, MD, † and Jianxing **Comptpols** (5**) Unknown primary tumours part I 10:45 - 11:30 45 Immunohistochemical classification of the MV (Am J Surg Pathol 2016;40:697–703) unknown primary tumour - part II 11:35 - 12:05 30 Optimization of antibodies, selection, protocols and SN





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,







Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee		
100000:15	15	Welcome and introduction	SN	
	45	Immunohistochemical principles:		
Oncogene (drivers) in Adenocarcinoma		The technical test approach – pre-analytical phase I	ON	
	45	Immunohistochemical principles:	ON	
		The technical test approach – pre-analytical phase II		
12:00 12:45	45	Immunohistochemical principles:	^e MB	ROS1
Gene	Mutation	The technical test approach - analytical phase I ⁴		
ROS1 (1%) 2 45 - 13:30 Gene KIF5B-RET (1.5%)	Fusion 45	Lunch	e	CD74-ROS1 (exon 32)
HER2 (=>) 3: 30 - 14-15 - EGFR (15%)	45	Immunohistochemical principles:	MB	CD74-POS1 (avon 24)
	4 -	The technical test approach - analytical phase	e	CD/4-RO31 (ex011 54)
14:20 - 15:05	45	Immunonistocnemical principles:	_ SN	F7R-ROS1
15.05 15.25	20			LENNOSI
15:05 - 15:25	20	Conee	e	I RIG3-ROS1
15:25 - 16:10	45	The technical test approach analytical phase II	SN	
16.15 17.00	45	Immunohistochomical classification of broact	e	SDC4-ROS1 (exon 32)
10.15 - 17.00	45		AVL	
17 00 - 19 00		Social arrangement (ontional) – Keglesnil (Skitt, Kiras	e	SDC4-ROS1 (exon 34)
Thursday, Sep	tembe	r 21 st Kinas	e	SLC3A42-ROS1 (exon 32)
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN	
		controls – breast tumours	e	SLC3A42-ROS1 (exon 34)
09:00 - 09:45	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part I	e	TPIVI3-ROS1
09:50 - 10:10	20	Coffee		FIC BOST
10:10 - 10:40	30	Optimization of antibodies, selection, protocols	SN	FIG-RUSI
		controls – unknown primary tumours part I	••••	
10:45 - 11:30	45	Immunonistochemical classification of the	MV	
11.25 12.05	20	unknown primary tumour – part II		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



Detection of fusion protein





Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,



09:30 - 10:00 1005:15 1005:1	15 45 A5 45 45	Arrival, coffee Welcome and introduction Immunohistochemical principles: The technical test approach – pre-analytical formation of the state of the	SN ON 3' ROS1 5' Fusion partners Variable region (riccides kinase domain) 5' SLC34A2, CD74, 3 SLC34A2, CD74, 3 SLC34A2, CD74, 3 WHAE, TFG, CEF	
KIFSB-RET (1.5%) HER2 (7%) BRAF (4%) MET (4%) MET (4%)	Amplification Aknown 45	Immunohistochemical principles: The technical test approach - analytical phase II	МВ	
14:20 - 15:05	45	Immunohistochemical principles: The technical test approach - post-analytical phase I	SN	
15:05 - 15.25	20	Coffee	×.	,
15:25 – 16:10 Table 5 Commerce	45 cially availabl	Immunohistochemical principles: eTabeា្ថ្ថម្នាស់លេខា testigapproach - post-analytical phase II	SN	
16: 15 – 17:00 Method	45 Manufacture	Immunohistochemical classification of breast rtumours Reagent	AVL	Regulatory status
17. <u>00 – 19.00</u> FISH	Cytocel1	Social arrangement (optional) – Keglespil (<u>Skittles</u>) ROS1 Dual Color Break Apart Probe		CE-IVD
Thursday, Sep	Distember Zyto Vision/2	Zytomed ZytoLight SPEC ROS1 Dual Color Break	Apart Probe	CE-IVD
08:15 - 09:00	Abbott 5	Optimization of antibroies, selection, proposols and	SN	RUO
	Cell Signalin	controls – breast tumours in Technologies – ROSI D4D6 rabbit monoclonal antibody		RUO
RT-PCR	45 AmoyDx	unknown primary tumotir ^{and} nare i gene fusion detection kit	IVI V	CE-IVD
09:\\$@ ^S - 10:10	Ther 20 Fish	Coffee Oncomine Fusion panel (ALK, ROS1, RE	T and NTRK1)	CE-IVD
10:10 - 10:40	Arch 30 x	Optimization of antibodiesPleetection, Rprotocolsvallanel	SN	RUO
10:45 - 11:30	45	controls – unknown primary tumours part I Immunohistochemical classification of the unknown primary tumour – part II	MV	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00	Arrival, coffee	
1000 Co:15 15	Welcome and introduction SN	
	Immunohistochemical principles:	/
Onegone (drivere) in Adenegoreineme	The technical tester approadhase prevanation on the second state of the second se	
Unknown (325%) 1:05 11:5 (RAS (35%) 45	Immunohistochemicaluprinciples: Reagent	Regulatory status
	The technical test approach – pre-analytical phase II	CE-IVD
12:00 12:45 45	Immunohistochemiczito stori zubies: ZytoLight SPEC ROS1 RugeColor Break Apart Probe	CE-IVD
Gene Mutation	The technical test approach - analytical phase IBreak-Apart FISH	RUO
ROSI (11) 45 - 13:30 Gene Fusion 45	Lunch IHC Cell Signaling Technologies ROS1 D4D6 rabbit monoclonal antibody	RUO
HER2 1,3:30 - 14:15 Gene Amplification 45	Immunohistochemical principles: ALK and ROS1 gene fusion detection kit	CE-IVD
BRAF (4%) EGFR (15%)	The technical test approach - analytical phase II	RUO
14:20 ^{mer(4%)} 15:05 45	Immunohistochemical principles:	
	The technical test approach - post-analytical phase I	
15:05 – 15.25 20	Coffee	
15:25 – 16:10 45	Immunohistochemical principles:	
Detection of chromoso	The technical test approach - post-analytical phase II	
16:15 - 17:00 45	Immunohistochemical classification of breast	
changes	tumours	
17.00 - 19.00	Social arrangement (optional) – Keglespil (<u>Skittles</u>)	
Thursday, September	r 21 st	
08:15 - 09:00 45	Obtimization of antibodies, selection, protocols and or Break Apart Probe	CE-IVD
Chr 6	controls - breast Vision ZytoPied ZytoLight SPEC ROST Dual Color Break Apart Probe	CE-IVD
09:00 - 09:45 5	Immunohistocherfical classification of the OS 1 Break-Apart MSH	RUO
KO2T -	unknown primary tumour – part I	
09:50 - 10:10 Ros1-c 20	Coffee	
10:al-0 - 10:40 🗧 30	Optimization of antibodies, selection, protocols and	
	controls – unknown primary tumours part I	
10:45 – 11:30 🗧 45	Immunohistochemical classification of the	
CD74-ROS1	unknown primary tumour – part II	
11:35 – 12:05 30	Optimization of antibodies, selection, protocols and SN	



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,



09:30 - 10:00		Arrival, coffee			
	.5	Welcome and introduction	SN		
	15	Immunohistochemical principles: The technical testapproachassypreamativitical phase I	ON	,	
Unknown (325%) 1:05 11:50 RRAS (35%)	5	Immunohistochemicaluprinciples: Reagent	ON	Regulatory status	
12:00 12:45 4	15	The technical test approach – pre-analytical phase II ROSI Dual Color Bre Immunohistochemical principles: ZytoLight SPEC ROS	ak Apart Probe 1 MapColor Break Apart Probe	CE-IVD CE-IVD	
Gene Mutation		The technical test approach - analytical phase IBreak-Apart F	ISH	RUO	
ROS1 (1%) Gene Fusion 4	-5	Lunch IHC Cell Signaling Technologies ROS1 D4D6 rabbit m	onoclonal antibody	RUO	
HER2 (=)3:30 14:15 Unknown 4	-5	Immunofiistochemical principles:	el MIR ROSI RET and NTRK1)	CE-IVD	
BRAF (4%) ALK (5%)		The technical test approach - analytical phase II and ALK, R	ET. ROS1 v2 Panel	RUO	
14:20 ^{mer (4%)} 15:05 4	5	Immunohistochemical principles:	<u>EN</u>		_
		The technical test approach - post-analytical phase I	511		
15:05 - 15.25 2	20	Coffee			
15:25 - 16:10 4	15	Immunohistochemical principles:			
10120 10110		The technical test approach - post-analytical phase II	SN		
16:15 – 17:00 4	15	Immunohistochemical classification of breast tumours	AVL		
Detaction ⁹ of fusion	RN	Social arrangement (optional) – Keglespil (Skittles)			
Thursday Sentem	hor	71 st			
	ibei	21			
08:15 - 09 00 200 COVARC	US1 (exon 32)	Optimization of antibodies, selection, protocols and controls – breast tumours	SN		
09:00 - 09:45 Kinase EZR-4	5	Immunehistochemical classification of the ALK and ROS	MY fusion detection kit	C	CE-IVD
635	ROS1	unknown primary tumour - part I	on panel (ALK ROS1 RET and NTRK)		CE-IVD
09:50 - 10 10 Kinse SDC4 2	exon 32)	Coffee ArcherDy EusionPleyTM A	JK RET ROS1 v2 Panel	R R	RUO
10:10 - 10:10 Kinase SLC4 20 32 Kinase SLC3A42	2-ROS1 (exon 34)	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN	IX.	100
10:45 - 11:30 Kine Fig.805	15 51	Ímmunohistochemical classification of the unknown primary tumour – part II	MV		
11:35 – 12:05 3	80	Optimization of antibodies, selection, protocols and	SN		





Wednesday, September 20th

09:30 - 10:00Arrival, coffee welconcogene drivers' in Adenocarcinoma 10:00 - 10:1515 10:15 - 11:0045 Immunohistochemical principles: ON Unknown The technical test approach - pre-analytical phase As (35%) 11:05 - 11:50 45 Immunohistochemical principles: ON The technical test approach – pre-analytical phase II 12:00 - 12:45 45 Immunohistochemical principles: MB The technical test approach - analytical phase I 12:45 - 13:30 45 Lunch 13:30 - 14:15 45 Immunohistochemical principles: MB The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN Gene Mutation The technical test approach - post-analytical phase I 15:05 - 15.2520 Coffee 45os1 Immunohistochemical principles: 15:25 - 16:10 SN Gene Fusion The technical test approach - post-analytical phase II KIE **45**RET Immunohistochemical classification of breast 16:15 - 17:00 AV - Gene Amplification tumours Unknown 17.00 - 19.00Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st EGFR (15%) 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and SN controls - breast tumours 09:00 - 09:4545 Iminunohistochemical classification of the MV unknown primary tumour – part I 09:50 - 10:10Coffee 20 10:10 - 10:4030 Optimization of antibodies, selection, protocols and SN controls - unknown primary tumours part I 10:45 - Near future unohistochemical classification of the MV unknown primary tumour – part II Optimization of antibodies, selection, protocols and 11:35 - 12:05 30

SN

Region Syddanmark Svaehus Lillebælt

Immunohistochemcal classification of

Lung cancer,



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

weunesuay,	Septen	IDEI 20	lout concuration and
09:30 - 10:00		Arrival, coffee	Next generation seq.
10:00 - 10:15	15	Welcome and introduction	SN SN
10:15 - 11:00	45	Immunohistochemical principles:	
Possible,		The technical test approach – pre-analytical phase I	
11:05bable 1:50	45	Immunohistochemical principles:	
or definite		The technical test approach – pre-analytical phase I	
12.00 - 12.45	45	Immunohistochemical principles:	MB
Reflex		The technical test approach - analytical phase I	
12:45 detision 30	45	Lunch 🛄 🧰 🚾	RAS, EGFR, BRAF, PIK3CA, AKT1, ERBB2, PTEN, NRAS, STK11, MAP2K1,
13:30 - 14:15	45	Immunohistochemical principles:	.K, DDR2, CTNNB1, MET, TP53, SMAD4, FBX7, FGFR3, NOTCH1, ERBB4, SER1_FG MP
		The technical states proacher analytical phase II	
14: <u>20 – 1</u> 5:05 _{Molecular}	45	Immunohistochemical principles:	SN
testing		The technical test approach - post-analytical phase	I
15:05 - 15.25	20	Coffee RNA workflow	
	45 Tumor	Immunohistochemical principles:	SN
by MDT	sample	The technical test approach post-analytical phase	
16:15 - 17:00	45	Immunohistochemical classification of breast	A, RET, RUST, and MTRAT fusion transcripts, in addition to targets designed
Patient is never or		tumours Ion AmpliSeq"RNA Ion POM" Ion Reporter" Fusion Lung Cancer Sequencer Software	Leter and ALA gene expression
Iong-time ex-emoker		Social arrangement (optional) – Keglespil (<u>Skittle</u>	<u>s</u>)
	ptembe	r 21 st Construct library and prepare template NBS Analysis and fusion detection	
08:15-09:00	45	Optimization of antibodies, selection, protocols ar	
Ī		controls – breast tumours	
09 00 - 09 45	45	Immunohistochemical classification of the	MV
carcinoma		unknown primary tumour – part I	
0 e.g. squamous, 10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols ar	nd _{SN}
		controls – unknown primary tumours part I	
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part II	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols ar	^{1d} SN



09:30 - 10:00

Wednesday, September 20th

Lung cancer, diagnosis and prediction. ptember 20th Arrival, coffee

Immunohistochemcal classification of



NanoString

10:00 - 10:15	15	Welcome and introduction	SN	1 141
10:15 - 11:00	45	Immunohistochemical principles:		
Possible,		The technical test approach – pre-analytical phase I	UN	
11:05bable 1:50	45	Immunohistochemical principles:	ON	
or definite		The technical test approach – pre-analytical phase II	UN	
12.00 - 12.45	45	Immunohistochemical principles:	MB	anstitute
Reflex	Step	The technical test approach - analytical phase I		
	Hypri	dization	_	
13:30 - 14:15	45	Immunohistochemical principles:	MB	BAAS .
		The technical test approach standytical phase II		
14 <u>20 – 1</u> 5 05 _{Molecular} 5 05	45	Immunohistochemical principles:	SN	
testing		The technical test approach - post-analytical phase I	0	
15:05 15:25	20	Coffee		
	45	Immunohistochemidal protopent	SN	
by MDT		The technical test approach - post-analytical phase II	SN	
16:15 - 17:00	45	Immunohistochemical classification of breast	Δ\/Ι	
Patient is never or		tempurs z 🛑 🗰 🦰 🦰		
Ichg-time ex-smoker	\rightarrow	Social arrangement (optional) – Keglespil (Skittles)	עוכ	ER™
(MDT discussion or pro-ompilion y, Sept	tembe	Pata Analysis Target 2: 2	nalysis	Software
08:15-09:00	45	Optimization of antibodies, selection, protocols and	CN	
Ī		controls – breast tumours	SIN	
09 00 - 09 45	45	Immunohistochemical classification of the	MV	
carcinoma		unknown primary tumour – part I		
0 e.g. squamque, 10	20	Coffee		
10.10 - 10.40	30	Optimization of antibodies, selection, protocols and	SN	
		controls – unknown primary tumours part I	31	
10:45 - 11:30	45	Immunohistochemical classification of the	MV	
		unknown primary tumour – part II		
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	
Patient selection in lung cancer: Evolution over time





Immunohistochemcal classification of

Lung cancer,



Wednesday, S	epter	nber 20 th T-cell	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	
		The technical test approach – pre-analytical phase I	UN
11:05 - 11:50	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase II	ON
12:00 - 12:45	45	Immunobistochemical principles:	MB
		The technical test approach - analytical phase I +	IND
12:45 - 13:30	45	Lunch	
13:30 - 14:15	45	Immunohistochemical principles:	MB
		The technical test approach - analytical phase II	
14:20 - 15:05	45	Immunohistochemical principles:	I receptor
	20	The technical test approach - post-analytical phase I	
15:05 - 15.25	20	Coffee	
15:25 - 16:10	45	Immunonistochemical principles:	SN
	45	Ine technical test approach - post-analytical phase IP	nugen
10:15 - 17:00	45	Thimehonistochemical classification of breast PDL1	AVL
17 00 - 19 00		Social arrangement (ontional) - Keglesnil (Skittles)	
17.00 19.00		atezolizumab	
Thursday, Sept	embe	r 21 st	
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	CN
		controls – breast tumours	211
09:00 - 09:45	45	Immunohistochemical classification of the	MV
		unknown primary tumour – part I	
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and	SN
		controls – unknown primary tumours part I	SIL
10:45 - 11:30	45	Immunohistochemical classification of the	MV
		unknown primary tumour – partisdLc cell	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



Immunohistochemcal classification of

Lung cancer,



Wednesday, S	epten	nber 20 th T-cell	
09:30 - 10:00		Arrival, coffee	
10:00 - 10:15	15	Welcome and introduction	SN
10:15 - 11:00	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase I	UN
11:05 - 11:50	45	Immunohistochemical principles:	ON
		The technical test approach – pre-analytical phase II	on
12:00 - 12:45	45	Immunobistochemical principles:	MB
12 15 12 20	4-	The technical test approach - analytical phase I +	
12:45 - 13:30	45		
13:30 - 14:15	45	Immunohistochemical principles:	MB
14.20 15.05	46	Ine technical test approach - analytical phase II	
14:20 - 15:05	45	The technical pert approach - pert applytical phase I	I receptor
15.05 - 15.25	20	Coffee	
15.05 - 15.25 15.25 - 16.10	20 45	Immunohistochemical principles	
15.25 10.10	75	The technical test approach - post analytical phase mor a	SN
16:15 - 17:00	45	Immunohistochemical classification of breast	
		tumours PDL1	AVL
17.00 - 19.00		Social arrangement (optional) – Keglespil (Skittles)	
Thursday Sont	ombo	atezolizumab	
mulsuay, Sept			
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	SN
Prodictivo	ma	controls – breast tumours	
	1 1460	Inclusion primary turbours part I	MV
00.50 10.10	20	Coffee	
10.10 - 10.10	20	Optimization of antihodion coloction protocolo and	
10.10 - 10.40	30	controls - unknown primary tumours part I	SN
10.45 - 11.30	45	Immunohistochemical classification of the	
10175 11.50	75	unknown primary tumour – partstatic cell	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	CN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th



Lung cancer,





Wednesday, September 20th

09:30 - 10:00Kromogen (farvestof)rival, coffee 10:003-10:15 Welcome and introduction SN 15 10:15 - 11:0045 Visualiseringssyste Immunohistochemical principles: ON The technical test approach – pre-analytical phase I (enzymer) 11:05 11:50 Sekundægsntistofmmunohistochemical principles: ON Primært antistof The technical test approach - pre-analytical phase II 12:00 - 12:45 Antigen 45 Immunohistochemical principles: MB Cellens cytoplasm The technical test approach - analytical phase I Cellekerne 45 12:45 - 13:30 Lunch 13:30 - 14:15 45 Immunohistochemical principles: MB The technical test approach - analytical phase II 14:20 - 15:05 45 Immunohistochemical principles: SN The technical test approach - post-analytical phase I 15:05 - 15.25Coffee 20 40x 40x 1+: Weak Staining Immunohisto Regative Staining 15:25 - 16:10 45 SN The technical test approach - post-analytical phase II 16:15 - 17:0045 Immunohistochemical classification of breast AVL tumours 17.00 - 19.00Social arrangement (optional) - Keglespil (Skittles) Thursday, September 21st 08:15 - 09:00 45 Optimization of antibodies, selection, protocols and SN controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the MV unknown primary tumour - part I 09:50 - 10:10 Coffee 20 10:10 - 10:4030 Optimization of antibodies, selection, protocols and SN controls -24nkwowderranerStamours part 40x 3+: Strong Stainin 10:45 - 11:30 45 Immunohistochemical classification of the MV unknown primary tumour - part II

11:35 – 12:05 **30** Optimization of antibodies, selection, protocols and SN



Immunohistochemcal classification of

Lung cancer,



Wednesday, September 20th

Immunohistochemcal classification of

Lung cancer,

diagnosis and prediction.



E1L3N antibody

SP142 antibody

09:30 - 10:00		Arrival, coffee	1. 10/9	· m. with that I show it
10:00 - 10:15	15 👝	Welcome and introduction	SN	and a star (and - pla
10:15 - 11:00	45	Immunohistochemical principles:	ON	· General Arts Charles State
		The technical test approach – pre-analytical phase I	ON	
11:05 - 11:50	45	Immunohistochemical principleန္နီ	ON	States States and
	-	The technical test approach – pre-analytical phase II	PIN	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
12:00 - 12:45	-45	Immunohistochemical principles:	MB	and the second
	a i	The technical test approach - analytical phase I		
12:45 - 13:30	45	Lunch	2.01	1 CO & 3 MAY 4 94 14
13:30 - 14:15	.45	Immunohistochemical principles:	MB	1. The Contract of the Contrac
14 2000	Contraction of	The technical test approach - analytical phase II		
14:20 7 15:05	45	Immunohistochemical principles: 100 µm	SN	100 μm
	S. A.S.	The technical test approach - post-analytical phase I		
15:05 - 15.25	20	Coffee		
15:25 - 16:10	45	Immunohistochemical principles:	SN	
	1	The technical test approach - post-analytical phase II	1	
16:15 - 17:00	45	Immunohistochemical classification of breast	AVL	A SALE AND A SALE OF
17.00 10.00				ATTA A STATE AND AND A
17.00 - 19.00	· •	Social arrangement (optional) – Regiespii (<u>Skittles</u>)	1 P 3	11 1 1 1 1 3 3 4 S 1 4 6
Thursday, Septe	embe	r 21 st	0.0.0	A CARLES AND A CARL
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	States and the second
	1.00	controls breast tumours	SN	A COLORING TO THE PARTY
09:00 - 09:45	45	Immunohistochemical classification of the	MV	A ST THE ALL ST THE
	No all and a	unknown primary tumour – part I	10.0	8.8- 4.35 es - 1 - 1 - 87
09:50 - 10:10	20	Coffee	Lang 2	A STATE AND A STATE AND A STATE
10:10 ¹ mr0:40	30	Optimization of antibodies, selection protocols and		100 µm
		controls – unknown primary tumours part I	SN	
10:45 - 11:30	45	Immunohistochemical classification of the	N/1\/	
		unknown primary tumour – part II	I''I V	117
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN	



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:30 - 10:00		Arrival, coffee					
10:00 - 10:15	15	Welcome and introduction		SN			
10:15 - 11:00	45	Immunohistochemical principles: The technical test approach – pre-analytical p	ohase I	ON			
fla: 11:50 Results of randomise	45 d phase III	Immunohistochemical principles: tithe technical test approachitopre Ghalferate	anges in the second	small-cell lung	cancer (NS	SCLC).	
12n00f-treadinesht	Dr 45	Immunohistochemical principles: 1 selection	ORR	MB ^{PFS} (mont	hs)	OS (month	ns)
12:45 - 13:30	45	The technical test approach - analytical phase Lunch	e I	Median	HR	Median	HR
13:30 - 14:15	Pe nts rol Nivolum	^{iz} Imnhunohi stechenî∂a l principiês‰ ^{na} The techni€ ir€esuab08 6ach ≥â‰ivtical phase	45% 11 ²⁶ %	10.4 МВ _{4.2}	0.50 1.15	NR 14.4	0.60 1.02
142:200d_bey59:005	Pembrol Pembrol	^{iz} អាអាម័យល្អនេះស្រុកស្រុង ស្រុកទៅទំនាំ។ ^{iz} ក្រអង់ក្នុងស្រុកទីដឹង principies:	18%	SN5.2	0.79 0.59	12.7 17.3	0.61 0.50
15:05 - 15.25	Ni zo un	hab Coffee Checkmate-017 No	20%	3.5	0.62	9.2	0.59
15:25 - 16:10	Ni yoj un Atezoliz	^{ual} Immunohistockentical principles: ^{um} the technical test approach ^N post-analytical	19% phase II	2.3 SN <u>2.8</u>	0.92 0.95	12.2 13.8	0.73 0.73

14681175viat171390RR, over 415 response on the set of t

17. QQttof 19. QQ was used for inclassial barrangement (aptional) - PKSglaspilr(Skittles)), OS and ORR (secondary end-points).

Thurstay, "September 214

08:15 - 09:00	45	Optimization of antibodies, selection, protocols and controls – breast tumours	SN
09:00 - 09:45	45	Immunohistochemical classification of the unknown primary tumour – part I	MV
09:50 - 10:10	20	Coffee	
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and controls – unknown primary tumours part I	SN
10:45 - 11:30	45	Immunohistochemical classification of the unknown primary tumour – part II	MV
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and	SN



Lung cancer,

diagnosis and prediction.



Program

Wednesday, September 20th

09:3	30 - 10:00		Arrival, coffee				
10:0	00 - 10:15	15	Welcome and intro	oduction		SN	
10::	L ^{æst_} 11:00	45 Vei	Immunohistochem ntahæstezteninal test	ical principles: ആണ്ടാമർദ്ദ (2)pre-analytic	adarko 28-b (3)	ON	Ventana SP142 (4)
11:0	05 – 11:50	45	Immunohistochem	ical principles:		ON	
12:0	Developed as)0 - 12:45	45	The technical test rvalumab Immunohistochem	Penibiolizumabrenanalytic ical principles:	Nipbiaseall Reidtal Myara	MB	Atezolizumab
12.	15 - 13.30			appiping a conditional and a lateral pu		(aaupc	(Genentech)
13:3	30 - 14:15 Instrument	45 _{VE}	NHANA BARharhem The technical test	ical principles:	Dako Autostain Jase II	¶MB	VENTANA BenchMark
14:2	20 - 15:05	45 0L	The technical test	ical principies:	LIIIK 40	SN	ULIKA
15:0)5 – 15.25 PD-L1 antibody	20 ^{Clc}	one SF263 (rabbit	Clone 22C3 (mouse	Clone 28-8 (rat	obit	Clone SP142 (rabbit
15:2	2516:10,	45 _{mo}	nocional) The technical test	approach - post-analytic	monoclonal) cal phase II	SN	monoclonal)
16::	15 - 17:00	45	Immunohistochem	ical classification of br	east	Δ\/I	Tumor cells and tumor-
17.0	Compartment 00 – 19.00	Tur	moticepointeembrane Social arrangemen	Tumor cell membrane It (optional) – Keglespi	Tumor cell mer I (<u>Skittles</u>)	ńbrane	infiltrating immune cells
Th	u rsidā(ş) , f S epte	embe	r 21 st	≥1%; ≥50% of tumor cells	≥1%; ≥5%; ≥10	% of tumor	≥50% of tumor cells
08:	Laigh (PD-Q0	45 ^{≥2∜}	⁵ ීමණ් ප්රේක්ෂිති controls – breast t	tibodies, selection, pro	tocols and cells (7)	SN	or ≥10% of tumor area
09:0	00 - 09:45	45	Immunohistochem unknown primary	ical classification of th tumour – part I	e	MV	
09:5	50 - 10:10	20	Coffee				
10::	10 - 10:40	30	Optimization of an controls – unknow	tibodies, selection, pro n primary tumours par	tocols and t I	SN	
10:4	45 - 11:30	45	Immunohistochem unknown primary	ical classification of the tumour – part II	e	MV	
11:3	35 - 12:05	30	Optimization of an	tibodies, selection, pro	tocols and	SN	



Lung cancer,

diagnosis and prediction.



Wednesday,	Septem	n Bear 200th of	Ventana	Dako	Dako
09:30 - 10:00		strainain coffee	SP263	22C3	28-8
10:00 - 10:15	15	Welcome and intr	oduction	INCOMPANY AND	SNEEDERS
10:15 - 11:00	45	Immunohistocher	mical principles:	NE EXESTING	ON
		The technical test	t approach – pre-anal	ytical phase I	
11:05 - 11:50	45	Immunohistocher	nical principles:		ON
	4 -	The technical test	t approach – pre-anal	ytical phase II	AND STORAGE
12:00 - 12:45	45	Immunonistocher	nical principles:	AS ALLANDS	MB
12.45 - 12.20	45		L approach - analytica	i pnase 1	20 Providence State
12.40 - 10.30	45 45	Immurphistocher	mical principles:	in the second	Star Star (1)
15.50 - 14.15	чJ	The technical test	t approach - analytica	I phase II	MB
14:20 - 15:05	45	Immunohistocher	mical principles:		1940 1
	_	The technical test	approach - post-ana	lytical phase I	SN
15:05 - 15.25	20	Coffee	and the state	at the state	A CALLER OF
15:25 - 16:10	45	Immunohistocher	mical principles:	1 marsh	SN
		The technical test	t approach - post-ana	lytical phase II	SIL SIL
16:15 - 17:00	45	Immunohistocher	nical classification of	f breast	AVE
17.00 10.00		tumours	An Alexandre	A Starter	Self Self
17.00 - 19.00		Social arrangeme	ent (optional) – Kegle	espii (<u>Skittles</u>)	1435 Variate
Thursday, Se	ptembe	r 21 st			
08:15 - 09:00	45	Optimization of a	ntibodies, selection,	protocols and	
		control – breast	tumours	A State of the	SIV
09:00 - 09:45	45	Immunohistocher	mical classification of	f the	MV
		unkhowh/primary	tumour – part I		
09:50 - Publice Olired inst January	10, 2017; DOI: 210/1078-04	2 Golfee			
	30		ntibodies, selection,	protocols and	SN
Agreement between Prog 1 ∩ Lignat⊓d-1 Driagnopskic Assa	grammed Cell D ys acro % M ultip	eation() let mmunobictochor	wh primary turnours	part I f tho	
Protein Expression Cutof	fs in Non-Small	cell unknown nrimary	r tumour – nart II		MV
Marjame J. Ratcliffel Alan Sherpe ² , Anit. 11 Paul Sorer ² , Hythaz Al-Marjo, Marlon C	a Midha ¹ , Crais Barker ² , Ma C. Rebelatto ⁴ 3 O ill Walk	ere Optimization of a	ntibodies, selection,	protocols and	SN

120



Wednesday, September 20th

09:30 - 10:00Arrival, coffee 10:00 - 10:15Welcome and introduction SN 15 10:15 - 11:0045 Immunohistochemical principles: ON The techonal test approach – pre-analytical phase I 11:05 - 11:50 45 Immunohistochemical principles: Ventana SP263 total (n = 493) ON The technical test approach – pre-analytical phase II Dako 22C3 total (n = 493) Immund Astonemical principles: 12:00 - 12:4545 MB Dako 28-8 total (n = 493) The technical test approach - analytical phase I 12:45 - 13:30 45 Lunch Immunohistochemical principles: 13:30 - 14:1545 MB The Rechnical test approach - analytical phase II 14:20 - 15:05 Figure 3. 45 Immunohisto hemical principles: SN The technical test approach - post-analytical phase I PD-L1 expression by bins (all samples Coffee by assay) 15:25 - 16:10 45 Immunohistochemical principles: SN The technical test approach - post-analytical phase II Immunohistochemical classification of breast 16:15 - 17:0045 tumours $0 \downarrow$ 40¹⁵⁹ 60,69 10-79 100 Social arrangement (bptional) - Reglessil (Spittless 17.00 - 19.00Thursday, September 21st 08:15 - 09:00 45 Optimization of antibodies, stelerotion, eprotected spendentage staining bin (%) controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the MV unknown primary tumour - part I 10.1158/1078-0422.CCR-16-2375 09:50 - 10:10 antibodies, selection, protocols and 10:10 - 10:4030 SN Agreement between Programmed Cell Death controls – unknown primary tumours part I Ligand-1 Diagnostic Assays across Multiple Immunohistochemical classification of the Protein Ethession dutois in Non-Small 45 MV Lung Cancer 😒 unknown primary tumour - part II $\begin{array}{l} \label{eq:mainless} \text{Marianne J. Ratcliffe}, \text{Alan Sharpe}^2, \text{Anita Midha}^1, \text{Craig Barker}^2, \text{Marietta Scott}^2\\ \text{Paul Scorer}^2, \text{Hydram Al-Masri}^3, \text{Marion C. Pebelatto}^4, \text{and Jill Walker}^2\\ \text{III:} 35 - \text{II2:} 05 \end{array}$ Optimization of antibodies, selection, protocols and SN

Region Syddanmark Sygehus Lillebælt

Immunohistochemcal classification of

Lung cancer,



Lung cancer,

diagnosis and prediction.



Program Wednesday, September 20th 03/05/2017 22.2 09:30 - 10:00Arrival, coffee 10:00 - 10:15Infetcontephylaphesintroassessments Protocols Controls Esvaents → Login Immunohistochemical principles: 10:15 - 11:00 ON The technical test approach – pre-analytical phase I PD-L1: Click to learn about the NordiQC initiatives 11:05 - 11:5045 Immunohistochemical principles: ON The technical test approach - pre-analytical phase II Hevents Events 12:00 - 12:45 45 Immunohistochemical principles: MARNordiQC Conference on Applied The technical test approach - analytical phase I Immunohistochemistry 12:45 - 13 30 Lunch 6–9 Jun 2017: Aalborg, Denmark 13:30 - 14:15 Immunohistochemical principles: 1st Copenhagen Surgical Pathology Update 2017 The technical test approach - analytical phase II 19–17 Jun 2017: Copenhagen, 14:20 - 15:05 45 Immunohistochemical principles: Denmark SN The technical test approach - post-analytical phase I NordiOC Workshop in Diagnostic 15:05 - 15 25 Coffee 20 Immunohistochemistry 20-22 Sep 2017: Aalborg, DK 15:25 - 16:10 45 Immunohistochemical principles: The technical test approach - post-analytical phase II 4th Diagnostic Immunohistochemistry 16:15 - 17:00 45 Immunohistochemical classification of breast for Pathologists ALL_20 Oct 2017: Krakow, Poland tumours 17.00 - 19.00Social arrangement (optional) – Keglespil (Skittles) Important dates Thursday_ASeptember 21st B3 Run 50 Publication of results 08:15 - 09:0045 Optimization of antibodies, selection, protocols and SN 10 Jul 2017 controls - breast tumours 09:00 - 09:4545 Immunohistochemical classification of the MV ² Ouestions unknown primary tumour - part I Check out our FAQ (Frequently asked 09:50 - 10:1020 Coffee questions) or contact us 10:10 - 10:4030 Optimization of antibodies, selection, protocols and SN Run 49, low molecular weight cycle section in the right too weak staining of appendix (B1) and liver (B2) due to (A2) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to 10:45 - 11; 30 less successful n45 AM5.2. Instruction to the right too weak staining of appendix (B1) and liver (B2) due to (A3) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to 10:45 - 11; 30 less successful n45 AM5.2. Instruction to the right too weak staining of appendix (B1) and liver (B2) due to (A3) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to (A3) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to (A3) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to (A4) and small cell lung carcinoma (SCLC) (A3). To the right too weak staining of appendix (B1) and liver (B2) due to (B1) and (B1) and liver (B2) and (B1) and Custom § Search MV Results - module 49, B23, H11 & C1 available **30** Optimization of antibodies, selection, protocols and 11:35 - 12:05 SN



Program Sufficient results





Assessment Run C3 2018 PD-L1 Amended version May 14th 2018§

Suff.

 OPS^2

92%

100%

100%

Wednesday is Septembers 20th Participated in this assessment and 91% achieved a sufficient mark. 09:30 - 10.00 essment marks for THCaPD-offeesays and PD-L1 antibodies are summarized in Table 3 (page 3).

10:00 - 10:15 Welcome and introduction Table 3. Assessment marks for IAC assays and antibodies run C3, PD-L1 IHC SN 10:15 - 11: CE-IVD / FDA approved n Vendor Optimal Good Borderline Poor Suff.¹ PD-L1 assays 11:05 - 11ON SP263, 790-4905 0 90% The technie test aboroach - pre-analytical Shase II 5 12:00 - 12 2 2 2 3, 790-42 5³ Immunohystoetheraftal principles: 0 0 ΜB 22C3 pharmDX, SKOOF he techned a head teat a pproach - analytical chase I 0 93% Ealible for 12:45 - 13: 20C3 pharmD4,5K006tinch8 1 IHC TPS SCS 00 treatment** Dako/Agilent 2 4 1 Cell line controls*** 1 100% _{NA} 0

13:30 – 14:258 pharmD 45K005 mm Enohisto cheemical principles: 1-4. Cell lines MB 4 SP142, 740-4859⁵ The technicatatestoapproach - analytical phase II Tissue controls

14:20 15:05	- 15 - 15	Antibodies ⁶ for laboratory develope PD-L1 assays, conc. antibody	ed Vendor	Optimal	Good	5. Tonsil 6. Tonsil 7 Broaccherline NSCLC	na Na Pooina	Suff. ¹ N	^{IA} Suff. IA OPS ²
15:25	- 16	mAb clone 2203	Immunonistochemical principles	- ₂₇	4	9. NSCLC	No ⊲ O Low	1% N 1-49 927% N	lo/No lo/Yes100%
16:15	- 17	mAb clone E1L3N :00 45 mAb CAL10	The technical jest approach - po Immunohistochemical classificat tumours zytomed Systems	st-aŋaiyi ion of b 1	iicai ₃ pha ireast 2	11. NSCLC 12. NSCLC 13. NSCLC	0 ^{High} No < /L 1 ^{Low} High	^{≥50} 100% ^Y 1% N ¹⁻⁴⁹ 60% ^N ≥50% Y	es/Yes lo/No ^{lo/Yes} 100% es/Yes

17.00 - 19.00 Ab clone 28-8 Social arrangement (optional) - Keglespil (Skittles)

Thursda	ym Septen 3ber	• 21 st 1	Cell Marque Zeta Corporation	2	0	0	0	-	<	
08:15 – 09	AnAb clone QAP	Optimiza	ationreftantipodies, sele	ction, p	rotoçols	and ₀ S	N 0	-		97
	rmAb BSR90	controis	Nordicast tumours	1	0	0	0	-	A Pres	$\boldsymbol{\mathcal{T}}$
09:00 - 09	rhnAb clone SP142 ⁵	Immuno	nistochemical classifica	uon _o or t	ne ₁	0	V ₀	-	Y -)	>
09:50 - 10	Total	UTIKITOWI 146 Coffee	i primary tumour – par	108	25	8	5	-	-	

09:50 - 10 10 20 74% 17% 3% 6% 91% oportion 10:10 - 10 49 Proportion of sufficient stains (optimal of good): 2) Proportion of sufficient stains with optimal protocols and

10:45 – 11:49 RTU system developed for the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semil-automated systems (Autostainer Eink48) but used by a provide the Agilent/Dako semilation of the Agilent of the Agilent/Dako semilation of the Agilent/Dako semilation of platforms (Ventana Bench unknownkoppimie)ry tumour - part II

11:35 - 12:05 30 Optimization of antibodies, selection, protocols and SN



Lung cancer,



Program		
Wednesday, Se	ptem	nber 20 th
09:30 - 10:00		Arrival, coffee
10:00 - 10:15	15	Welcome and introduction SN
10:15 - 11:00	45	Immunohistochemical principles:
Cyto	loa	The technica approach – pre-analytical phase I
11:05 - 11:50	45	Immunohistochalminal principles: Periferal tumor
		The technical test approach – pre-analytical phase II
12:00 - 12:45	45	Immunohistochemical principles:
		The technical test happing a ch - analytical phase I
12:45 - 13:30	45	Lunch Bronchial lavage, Course needle
13:30 - 14:15	45	Immunohistochemicali principles: blopsi MB
14.20 15.05	45	Immunohistochomical principles
14.20 - 15.05	45	The technical test approach - post-analytical phase I
15.05 - 15.25	20	Coffee
15.05 - 16.10	45	Immunohistochemical principles:
10.25 10.10	10	The technical test approach - post-analytical phase II SN Cytology
16:15 - 17:00	45	Immunohistochemical classification of breast
		tumours AVL
17.00 - 19.00		Social arrangement (diptional) tast the glespil (<u>Skittles</u>)
Thursday, Sente	mbe	r 21 st EBUS
	JY	ELIS, N.
08:15 - 09:00	45	Optimization of antibodies, selection, protocols and SN
00.00 - 00.45	45	Immut histochomical classification of the
09.00 - 09.45	43	unknown primary tumoun +: part I
09.50 - 10.10	20	Coffee M from motostasis suspekto
10:10 - 10:40	30	Optimization afactilia dieserse leation protocols and
10110		controls – unknown primary tumours part 1
10:45 - 11:30	45	Immunohistochemical classification of the
		Junknown primary tumouri – part II Operated
11:35 <u>- 12:05</u>	30	Optimization of antibodies, selection, photocols and SN



Lung cancer,





Lung cancer,



Wednesday, Septe	mber 20 th	T-cell		
09:30 - 10:00	Arrival, coffee			
10:00 - 10:15 15	Welcome and intr	roduction	SN	
10:15 – 11:00 45	Immunohistocher	mical principles:	ON	
	The technical test	t ap <mark>proach – pre-analytical phase</mark> I	UN	
11:05 – 11:50 45	Immunohistocher	mical principles:	ON	
	The technical test	t approach – pre-analytical phase II	on	
12:00 – 12:45 45	Immunobistacher	nical principles:	MB	
12.45 12.20 45	The technical test	t approach - analytical phase I -		
12:45 - 13:30 45				
13:30 - 14:15 45	Immunonistocher	mical principles:	MB	
14·20 - 15·05 4 5	Immunohistochor	nical principles:		
14.20 - 15.05 45	The technical test	approach - nest-analytical phase I	SN	
15:05 - 15.25 20	Coffee	pyt univited prase i		
15:25 – 16:10 45	Immunohistocher	mical principles:		
10110	The technical test	approach - post analytical phase 10	SN	=
16:15 – 17:00 45	Immunohistocher	nical classification of breast	A1/1	Future:
	tumours	PDL1	AVL	
17.00 - 19.00	Social arrangeme	ent (optional) – Keglespil (<u>Skitt/es</u>)		
Thursday, Septemb	er 21 ^{strumab}	2 A A A		
08:15 - 09:00 45	Optimization of a	ntibodies, selection, protocols and	Pro	dictivo markor
	controls – breast	tumours	SIN C	
09:00 - 09:45 45	Immunohistocher	mical classification of the	MV	mutations =
	unknown primary	tumour – part I		tumor antigens
09:50 - 10:10 20	Coffee			0
10:10 - 10:40 30	Optimization of a	ntibodies, selection, protocols and	SN	
	controls – unknow	wn primary tumours part L	SIL	
10:45 - 11:30 45	Immunohistocher	mical classification/of the	MV	
11.25 12.05	Unknown primary	tumour - parisdic cell		
11:35 - 12:05 30	-Optimization of a	nubodies, selection, protocols and	SN	

		The Diagnostic algorithm		
Nord	\frown	Day 3		
Program		PRELIMINARY		
Wednesday, S	epter	nber 20 th		
09:30 - 10:00		Arrival, coffeerification with		
10:00 - 10:15	15	Welcome and introduction Will SN		
10:15 - 11:00	45	Immunohi smennalisto ciples: The technical test approach – pre-analytical phase I ON		
11:05 - 11:50	45	Immunohistochemical principles:		
		The technical test approach – pre-analytical phase II		
12:00 - 12:45	45	Immunohietterherhietterhietterheren, OCLO		
12:45 - 13:30	45			
13:30 - 14:15	45	Immunohistochemical principles:	nswer	
		The technical test approach - analytical phase II		
^{14:20} – 15:05 Biopsy	45 M	Immunohistochemical principles: Of Revenues and test approach Otheragamalignant SN D	Day 2	Day 5-8
15:05 - 15.25	20	Coffee		Suppl
15:25 - 16:10	45	Immunohistochemical principles:		Suppi.
16.15 17.00	45	The technical test approach - post-analytical phase II		Answer
10:15 - 17:00	45	tumours a resolution of breast AVL		
17.00 - 19.00		Social arrangement (optional) - keglespil, (Skittles)	Molecu	ular analysis
Thursday, Sept	embe	r 21 st	ALK, (ROS, RET)
08:15 - 09:00	45	Optimization of antibodies, selection, proto Adenocarc	inoma EGFR	
00.00 00.45	46	control Subtyping with		
09:00 - 09:45	45	unknowhphihaity isite ur – part I	nswer	Day 3
09:50 - 10:10	20	Coffee and PDL1 analysis		
10:10 - 10:40	30	Optimization of antibodies, selection, protocols and SN	Day 3	Answer
10:45 - 11:30	45	Immunohistochemical classification of the	ooroinama	
101.10 11.00		unknown primary tumour – part II	scarcinoma	
11:35 - 12:05	30	Optimization of antibodies, selection, protocols and SNI		